Eli Lilly and (LLY) 10-K19 Feb 142013 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2013	Feb. 14, 2014	Jun. 30, 2013
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'Lilly Eli & Co	'	'
Entity Central Index Key	'0000059478	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Public Float	'	'	$46,911,000,000
Entity Common Stock, Shares Outstanding	'	1,119,713,084	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue	$23,113.10	$22,603.40	$24,286.50
Cost of sales	4,908.10	4,796.50	5,067.90
Research and development	5,531.30	5,278.10	5,020.80
Marketing, selling, and administrative	7,125.60	7,513.50	7,879.90
Acquired in-process research and development	57.1	0	388
Asset impairment, restructuring, and other special charges	120.6	281.1	401.4
Other-net, (income) expense	518.9	674	-179
Cost of sales, operating expenses, and other-net	17,223.80	17,195.20	18,937
Income before income taxes	5,889.30	5,408.20	5,349.50
Income taxes	1,204.50	1,319.60	1,001.80
Net income	$4,684.80	$4,088.60	$4,347.70
Earnings per share - basic	$4.33	$3.67	$3.90
Earnings per share - diluted	$4.32	$3.66	$3.90

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net income	$4,684.80	$4,088.60	$4,347.70
Other comprehensive income (loss)	'	'	'
Foreign currency translation gains (losses)	36.2	160.9	-244.8
Net unrealized gains (losses) on securities	204.3	88.5	-178.5
Defined benefit pension and retiree health benefit plans	-2,592.20	128.6	1,240.20
Effective portion of cash flow hedges	-123.8	8.7	44.8
Other comprehensive income (loss) before income taxes	2,708.90	129.5	-1,618.70
Provision for income taxes related to other comprehensive income (loss) items	-914.5	-68	430.2
Other comprehensive income (loss)	1,794.40	61.5	-1,188.50
Comprehensive income	$6,479.20	$4,150.10	$3,159.20

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and cash equivalents	$3,830.20	$4,018.80
Short-term investments	1,567.10	1,665.50
Accounts receivable, net of allowances of $100.3 (2013) and $108.5 (2012)	3,434.40	3,336.30
Other receivables	588.4	552
Inventories	2,928.80	2,643.80
Prepaid expenses and other	755.8	822.3
Total current assets	13,104.70	13,038.70
Other Assets	'	'
Investments	7,624.90	6,313.90
Goodwill and other intangibles, net	4,331.10	4,752.70
Sundry	2,212.50	2,533.40
Total other assets	14,168.50	13,600
Property and equipment, net	7,975.50	7,760.20
Total assets	35,248.70	34,398.90
Current Liabilities	'	'
Short-term borrowings and current maturies of long-term debt	1,012.60	11.9
Accounts payable	1,119.30	1,188.30
Employee compensation	943.9	940.3
Sales rebates and discounts	1,941.70	1,777.20
Dividends payable	523.5	541.4
Income taxes payable	254.4	143.5
Deferred income taxes	792.8	1,048
Other current liabilities	2,328.40	2,738.90
Total current liabilities	8,916.60	8,389.50
Other Liabilities	'	'
Long-term debt	4,200.30	5,519.40
Accrued retirement benefits	1,549.40	3,012.40
Long-term income taxes payable	1,078.70	1,334.30
Other noncurrent liabilities	1,863	1,369.40
Total other liabilities	8,691.40	11,235.50
Shareholders' Equity	'	'
Common stock	698.5	716.6
Additional paid-in capital	5,050	4,963.10
Retained earnings	16,992.40	16,088.20
Employee benefit trust	-3,013.20	-3,013.20
Accumulated other comprehensive loss	-2,002.70	-3,797.10
Cost of common stock in treasury	-93.6	-192.4
Total Eli Lilly and Company shareholders' equity	17,631.40	14,765.20
Noncontrolling interests	9.3	8.7
Total equity	17,640.70	14,773.90
Total liabilities and equity	$35,248.70	$34,398.90

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, except Share data in Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Accounts receivable, allowances	$100.30	$108.50
Issued shares, shares in thousands	1,117,628	1,146,493
Common stock shares in treasury, shares in thousands	833	2,850

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity Statement (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Trust for Benefit of Employees [Member]	Employee Stock Option [Member]
In Millions, except Share data in Thousands, unless otherwise specified	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Trust for Benefit of Employees [Member]	Employee Stock Option [Member]
Shareholders' equity, Beginning Balance at Dec. 31, 2010	$12,420.30	$721.30	$4,798.50	$12,732.60	($2,670.10)	($96.40)	($3,065.60)	'
Shares, Beginning Balance at Dec. 31, 2010	'	1,154,018	'	'	'	864	'	'
Increase (Decrease) in Shareholders' Equity [Roll Forward]	'	'	'	'	'	'	'	'
Net income	4,347.70	'	'	4,347.70	'	'	'	'
Other comprehensive income (loss)	-1,188.50	'	'	'	-1,188.50	'	'	'
Cash dividends	2,182.50	'	'	2,182.50	'	'	'	'
Retirement of treasury stock, shares	'	-1	'	'	'	-1	'	'
Retirement of treasury stock, value	0	'	-0.1	'	'	0.1	'	'
Issuance of stock under employee stock plans-net, shares	'	-4,627	'	'	'	-10	'	'
Issuance of stock under employee stock plans-net, value	104.9	2.8	108.7	'	'	1	'	'
Stock-based compensation	147.4	'	147.4	'	'	'	'	'
ESOP transactions	102.1	'	49.7	'	'	'	'	52.4
Stockholders' equity, other	0.1	'	'	'	'	'	'	'
Shareholders' equity, Ending Balance at Dec. 31, 2011	13,541.70	724.1	4,886.80	14,897.80	-3,858.60	-95.3	-3,013.10	'
Shares, Ending Balance at Dec. 31, 2011	'	1,158,644	'	'	'	853	'	'
Increase (Decrease) in Shareholders' Equity [Roll Forward]	'	'	'	'	'	'	'	'
Net income	4,088.60	'	'	4,088.60	'	'	'	'
Other comprehensive income (loss)	61.5	'	'	'	61.5	'	'	'
Cash dividends	2,186.50	'	'	2,186.50	'	'	'	'
Retirement of treasury stock, shares	'	-14,912	'	'	'	-14,912	'	'
Retirement of treasury stock, value	0.1	-9.3	'	-711.7	'	721.1	'	'
Issuance of stock under employee stock plans-net, shares	'	-2,761	'	'	'	-9	'	'
Issuance of stock under employee stock plans-net, value	62.4	1.8	65.2	'	'	-1	'	'
Purchase for treasury, shares	'	'	'	'	'	16,918	'	'
Purchase for treasury, value	819.2	'	'	'	'	819.2	'	'
Stock-based compensation	141.5	'	141.5	'	'	'	'	'
Stockholders' equity, other	-0.1	'	'	'	'	'	'	'
Shareholders' equity, Ending Balance at Dec. 31, 2012	14,765.20	716.6	4,963.10	16,088.20	-3,797.10	-192.4	-3,013.20	'
Shares, Ending Balance at Dec. 31, 2012	'	1,146,493	'	'	'	2,850	'	'
Increase (Decrease) in Shareholders' Equity [Roll Forward]	'	'	'	'	'	'	'	'
Net income	4,684.80	'	'	4,684.80	'	'	'	'
Other comprehensive income (loss)	1,794.40	'	'	'	1,794.40	'	'	'
Cash dividends	2,102.80	'	'	2,102.80	'	'	'	'
Retirement of treasury stock, shares	'	-32,406	'	'	'	-32,406	'	'
Retirement of treasury stock, value	0	-20.3	'	-1,677.80	'	1,698.10	'	'
Issuance of stock under employee stock plans-net, shares	'	-3,541	'	'	'	-11	'	'
Issuance of stock under employee stock plans-net, value	55.1	-2.2	58	'	'	-0.7	'	'
Purchase for treasury, shares	'	'	'	'	'	30,400	'	'
Purchase for treasury, value	1,600	'	'	'	'	1,600	'	'
Stock-based compensation	144.9	'	144.9	'	'	'	'	'
Shareholders' equity, Ending Balance at Dec. 31, 2013	$17,631.40	$698.50	$5,050	$16,992.40	($2,002.70)	($93.60)	($3,013.20)	'
Shares, Ending Balance at Dec. 31, 2013	'	1,117,628	'	'	'	833	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash Flows from Operating Activities	'	'	'
Net income	$4,684.80	$4,088.60	$4,347.70
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:	'	'	'
Depreciation and amortization	1,445.60	1,462.20	1,373.60
Change in deferred income taxes	285.9	126	-268.5
Stock-based compensation expense	144.9	141.5	147.4
Impairment charges, indefinite lived intangibles	0	205	151.5
Acquired in-process research and development, net of tax	37.1	0	252.2
Income related to termination of the exenatide collaboration with Amylin	-495.4	-787.8	0
Other operating activities, net	25.1	120.5	-17.8
Changes in operating assets and liabilities, net of acquisitions	'	'	'
Receivables - (increase) decrease	-152.7	361.8	-188.8
Inventories - (increase) decrease	-286.5	-307.9	203.1
Other assets - (increase) decrease	116.5	231	642.7
Accounts payable and other liabilties-increase (decrease)	-70.3	-336.1	591.4
Net Cash Provided by Operating Activities	5,735	5,304.80	7,234.50
Cash Flows from Investing Activities	'	'	'
Purchases of property and equipment	-1,012.10	-905.4	-672
Disposals of property and equipment	179.4	22	25.3
Proceeds from sales and maturities of short-term investments	3,320.10	2,547.50	1,807.90
Purchases of short-term investments	-1,531	-2,172.40	-2,058.80
Proceeds from sales and maturities of noncurrent investments	11,235	4,355.70	2,138.50
Purchases of noncurrent investments	-14,041.90	-7,618.60	-4,459.40
Purchase of product rights	-24.1	-138.8	-632.9
Purchases of in-process research and development	-57.1	0	-388
Cash paid for acquisitions, net of cash acquired	-43.7	-199.3	-307.8
Net change in loan to collaboration partner	0	165	-165
Proceeds from prepayment of revenue-sharing obligation	0	1,212.10	0
Other investing activities, net	-97.4	-100.6	-112.2
Net Cash Used for Investing Activities	-2,072.80	-2,832.80	-4,824.40
Cash Flows from Financing Activities	'	'	'
Dividends paid	-2,120.70	-2,187.40	-2,180.10
Net change in short-term borrowings	0	0	-134.1
Repayments of long-term debt	-10.5	-1,511.10	-61.7
Purchases of common stock	-1,698.10	-721.1	0
Other financing activities, net	0	0	6
Net Cash Used for Financing Activities	-3,829.30	-4,419.60	-2,369.90
Effect of exchange rate on cash and cash equivalents	-21.5	43.9	-110.9
Net decrease in cash and cash equivalents	-188.6	-1,903.70	-70.7
Cash and cash equivalents at beginning of year	4,018.80	5,922.50	5,993.20
Cash and Cash Equivalents at End of Year	$3,830.20	$4,018.80	$5,922.50

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation [Text Block]	'
	Note 1: Summary of Significant Accounting Policies
	Basis of presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders’ interests are reflected as a separate component of equity. All intercompany balances and transactions have been eliminated.
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing.
	All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of dilutive stock options and other incremental shares.
	Cash equivalents
	We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.
	Inventories
	We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental United States. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost.
	Investments
	Substantially all of our investments in debt and marketable equity securities are classified as available-for-sale. Investment securities with maturity dates of less than one year from the date of the balance sheet are classified as short-term. Available-for-sale securities are carried at fair value with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss). The credit portion of unrealized losses on our debt securities considered to be other-than-temporary is recognized in earnings. The remaining portion of the other-than-temporary impairment on our debt securities is then recorded, net of tax, in other comprehensive income (loss). The entire amount of other-than-temporary impairment on our equity securities is recognized in earnings. We do not evaluate cost-method investments for impairment unless there is an indicator of impairment. We review these investments for indicators of impairment on a regular basis. Realized gains and losses on sales of available-for-sale securities are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings. Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method with our share of earnings or losses reported in other–net, (income) expense. We own no investments that are considered to be trading securities.
	Risk-management instruments
	Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and do not create additional risk because gains and losses on derivative contracts offset losses and gains on the assets, liabilities, and transactions being hedged. As derivative contracts are initiated, we designate the instruments individually as either a fair value hedge or a cash flow hedge. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.
	For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change.
	We may enter into foreign currency forward contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.
	In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.
	Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements.
	We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.
	We may enter into forward-starting interest rate swaps as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the debt agreement.
	Goodwill and other intangibles
	Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized.
	Intangible assets with finite lives are capitalized and are amortized on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years.
	The costs of in-process research and development (IPR&D) projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed. The fair values of IPR&D projects acquired in business combinations are capitalized as other intangible assets. Several methods may be used to determine the estimated fair value of the IPR&D acquired in a business combination. We utilize the “income method,” which applies a probability weighting that considers the risk of development and commercialization, to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each project independently. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. For transactions other than a business combination, we also capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing and amortize those amounts over the remaining estimated useful life of the underlying asset.
	Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived IPR&D assets for impairment testing purposes, we utilize the "income method" discussed in the previous paragraph. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present.
	Property and equipment
	Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and 3 to 18 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.
	Litigation and environmental liabilities
	Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable. For substantially all of our currently marketed products, we are completely self-insured for product liability losses.
	Revenue recognition
	We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. Provisions for returns, discounts, and rebates are established in the same period the related sales are recognized.
	We also generate income as a result of collaboration agreements. Revenue from co-promotion arrangements is based upon gross margins reported to us by our co-promotion partners. Initial fees we receive from the partnering of our compounds under development where we have continuing involvement are generally amortized through the expected product approval date. For out-licensing agreements that include both the sale of marketing rights to our commercialized products and a related commitment to supply the products, the initial fees received are generally recognized in net product sales over the term of the supply agreement when we have determined that the marketing rights do not have value on a standalone basis. We immediately recognize the full amount of developmental milestone payments due to us upon the achievement of the milestone event if the event is objectively determinable and the milestone is substantive in its entirety. A milestone is considered substantive if the consideration earned 1) relates solely to past performance, 2) is commensurate with the enhancement in the pharmaceutical product's value associated with the achievement of the important event in its development life cycle, and 3) is reasonable relative to all of the deliverables and payment terms within the arrangement. Milestone payments earned by us are generally recorded in other–net, (income) expense. If the payment to us is a commercialization payment that is part of a multiple-element collaborative commercialization arrangement and is a result of the initiation of the commercialization period (e.g., payments triggered by regulatory approval for marketing or launch of the product), we amortize the payment to income as we perform under the terms of the arrangement. See Note 4 for specific agreement details.
	Royalty revenue from licensees, which is based on third-party sales of licensed products and technology, is recorded as earned in accordance with the contract terms when third-party sales can be reasonably measured and collection of the funds is reasonably assured. This royalty revenue is included in collaboration and other revenue.
	Research and development expenses and acquired IPR&D
	Research and development expenses include the following:

	•	Research and development costs, which are expensed as incurred.

	•	Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.
	Acquired IPR&D expense includes the initial costs of IPR&D projects acquired directly in asset acquisitions, unless they have an alternative future use.
	Income taxes
	Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S. and be taxable. When foreign earnings are expected to be indefinitely reinvested outside the U.S., no accrual for U.S. income taxes is provided.
	We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.
	Earnings per share
	We calculate basic earnings per share based on the weighted-average number of common shares outstanding and incremental shares. We calculate diluted earnings per share based on the weighted-average number of common shares outstanding, including incremental shares and dilutive stock options. See Note 13 for further discussion.
	Stock-based compensation
	We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. Under our policy, all stock-based awards are approved prior to the date of grant. The compensation committee of the board of directors approves the value of the award and date of grant. Stock-based compensation that is awarded as part of our annual equity grant is made on a specific grant date scheduled in advance.
	Reclassifications
	Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.

Implementation_of_New_Financia

Implementation of New Financial Accounting Pronouncements	12 Months Ended
Implementation of New Financial Accounting Pronouncements	Dec. 31, 2013
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Accounting Changes and Error Corrections [Text Block]	'
	Note 2: Implementation of New Financial Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board issued a clarification regarding the presentation of an unrecognized tax benefit related to a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. Under this new standard, the liability related to an unrecognized tax benefit, or a portion thereof, should be presented in the financial statements as a reduction to a deferred tax asset if available under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position. Otherwise, the unrecognized tax benefit should be presented in the financial statements as a separate liability. The assessment is based on the unrecognized tax benefit and deferred tax asset that exist at the reporting date. The provisions of the new standard are effective on a prospective basis beginning in 2014 for annual and interim reporting periods, with earlier adoption permitted. While we are still finalizing our determination of the impact of this standard on both our deferred tax assets and income taxes payable, we do not currently anticipate that the implementation of this standard will have a material impact on our consolidated balance sheets, and it will have no impact on our consolidated statements of operations.

Acquisitions

Acquisitions	12 Months Ended
Acquisitions	Dec. 31, 2013
Business Combinations [Abstract]	'
Acquisitions [Text Block]	'
	Note 3: Acquisitions
	During 2012 and 2011, we completed the acquisitions of ChemGen Corporation (ChemGen) and the animal health business of Janssen Pharmaceuticia NV (Janssen), respectively. These acquisitions were accounted for as business combinations under the acquisition method of accounting. The assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated financial statements from the date of acquisition. None of these acquisitions were material to our consolidated financial statements.
	In addition to the acquisitions of businesses, we also acquired assets in development in 2013 and 2011 which are further discussed below in Product Acquisitions and in Note 4, respectively. Upon acquisition, the acquired IPR&D related to these products was immediately written off as an expense because the products had no alternative future use. For the years ended December 31, 2013 and 2011, we recorded acquired IPR&D charges of $57.1 million and $388.0 million, respectively, associated with these transactions. There were no acquired IPR&D charges in 2012.
	In connection with the arrangements described below, our partners may be entitled to future milestones and royalties based on sales should these products be approved for commercialization.
	Acquisition of Businesses
	ChemGen
	On February 17, 2012, we acquired all of the outstanding stock of ChemGen Corporation, a privately-held bioscience company specializing in the development and commercialization of innovative feed-enzyme products that improve the efficiency of poultry, egg, and meat production, for total purchase consideration of $206.9 million in cash. In connection with this acquisition, we recorded $151.5 million of marketed product assets and $55.4 million of other net assets.
	Janssen
	On July 7, 2011, we acquired the animal health business of Janssen, a Johnson & Johnson company, for total purchase consideration of $307.8 million in cash. We obtained a portfolio of more than 50 marketed animal health products. In connection with this acquisition, we recorded $234.4 million of marketed product assets, $29.6 million of acquired IPR&D assets, and $43.8 million of other net assets.
	Product Acquisitions
	In December 2013, we acquired all development and commercial rights for a calcitonin gene-related peptide (CGRP) antibody currently being studied as a potential treatment for the prevention of frequent, recurrent migraine headaches for $57.1 million in cash. At the time of the purchase, the product had completed a successful Phase II proof-of-concept study and had no alternative future use. The related $57.1 million charge for acquired IPR&D was included as expense in the fourth quarter of 2013 and is deductible for tax purposes.

Collaborations

Collaborations	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Collaborations [Text Block]	'
	Note 4: Collaborations
	We often enter into collaborative arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These collaborations often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the third party. Revenues related to products we sell pursuant to these arrangements are included in net product sales, while other sources of revenue (e.g., royalties and profit-share payments) are included in collaboration and other revenue. For the years ended December 31, 2013, 2012, and 2011, we recognized collaboration and other revenue of $707.5 million, $633.0 million, and $681.7 million, respectively. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments made to or reimbursements received from our collaboration partners. Each collaboration is unique in nature, and our more significant arrangements are discussed below.
	Exenatide
	In November 2011, we agreed with Amylin Pharmaceuticals, Inc. (Amylin) to terminate our collaborative arrangement for the joint development, marketing, and selling of Byetta® (exenatide injection) and other forms of exenatide such as Bydureon® (exenatide extended-release for injectable suspension). Under the terms of the termination agreement, Amylin made a one-time, upfront payment to us of $250.0 million. Amylin also agreed to make future revenue-sharing payments to us in an amount equal to 15.0 percent of its global net sales of exenatide products until Amylin made aggregate payments to us of $1.20 billion plus interest, which would accrue at 9.5 percent. Upon completion of the acquisition of Amylin by Bristol-Myers Squibb Company in August 2012, Amylin's obligation of $1.26 billion, including accrued interest, was paid in full, with $1.21 billion representing a prepayment of the obligation. We would also receive a $150.0 million milestone payment contingent upon U.S. Food and Drug Administration (FDA) approval of a once-monthly suspension version of exenatide.
	Commercial operations were transferred to Amylin in the U.S. in late-2011. Outside the U.S., we transferred to Amylin exenatide commercial rights and control in all markets during the first quarter of 2013.
	Payments received from Amylin were allocated 65 percent to the U.S., which was treated as a contract termination, and 35 percent to the business outside the U.S., which was treated as the disposition of a business. The allocation was based upon relative fair values. The revenue-sharing income allocated to the U.S. was recognized as collaboration and other revenue, consistent with our policy for royalty revenue, while the income related to the prepayment of Amylin's obligation allocated to the U.S. was recognized in other-net, (income) expense. All income allocated to the business outside the U.S. that was transferred during the first quarter of 2013 was recognized as a gain on the disposition of a business in other–net, (income) expense, net of the goodwill allocated to the business transferred.
	Prior to termination of the collaboration, we and Amylin were co-promoting Byetta in the United States. Amylin was responsible for manufacturing and primarily utilized third-party contract manufacturers to supply Byetta. We supplied Byetta pen delivery devices for Amylin and will continue to do so for a period that will not extend beyond the first quarter of 2014. We were responsible for certain development costs related to certain clinical trials outside the U.S. that we were conducting as of the date of the termination agreement as well as commercialization costs outside the U.S. until the commercial rights were transferred to Amylin.
	Under the terms of our prior arrangement, we reported as collaboration and other revenue our 50 percent share of gross margin on Amylin’s net product sales in the United States. We reported as net product sales 100 percent of sales outside the U.S. and our sales of Byetta pen delivery devices to Amylin. We paid Amylin a percentage of the gross margin of exenatide sales outside of the U.S., and these costs were recorded in cost of sales. This arrangement for the commercial operations outside the U.S. continued until those rights were transferred to Amylin during the first quarter of 2013. Prior to termination of the agreement, under the 50/50 profit-sharing arrangement for the U.S., in addition to recording as revenue our 50 percent share of exenatide’s gross margin, we also recorded approximately 50 percent of U.S. related research and development costs and marketing and selling costs in the respective line items on the consolidated statements of operations.
	In accordance with the prior arrangement and pursuant to Amylin’s request, we loaned Amylin $165.0 million in the second quarter of 2011. This loan and related accrued interest were paid in full in August 2012.
	The following table summarizes the revenue and other income recognized with respect to exenatide:


		2013		2012		2011
	Net product sales	$	133.1	$	207.8	$	179.6

	Collaboration and other revenue	—		70.1		243.1

	Total revenue	$	133.1	$	277.9	$	422.7


	Income related to termination of the exenatide collaboration with Amylin(1)	$	495.4	$	787.8	$	—

	1 Presented in other-net, (income) expense
	Effient®
	We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. We and Daiichi Sankyo co-promote Effient in certain territories (including the U.S. and five major European markets), while we have exclusive marketing rights in certain other territories. Daiichi Sankyo has exclusive marketing rights in Japan and certain other territories. The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories. We record product sales in our exclusive and co-promotion territories. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. Profit-share payments made to Daiichi Sankyo are recorded as marketing, selling, and administrative expenses. All royalties paid to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. Effient sales were $508.7 million, $457.2 million, and $302.5 million for the years ended December 31, 2013, 2012, and 2011, respectively.
	Erbitux®
	We have several collaborations with respect to Erbitux. The most significant collaborations are in the U.S., Canada, and Japan (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). Upon expiration of the agreements, all of the rights to Erbitux in the U.S. and Canada return to us and certain rights to Erbitux outside the U.S. and Canada will remain with Merck KGaA (Merck).
	The following table summarizes our revenue recognized with respect to Erbitux:


		2013		2012		2011
	Net product sales	$	58.5	$	76.4	$	87.6

	Collaboration and other revenue	315.2		320.6		321.6

	Total revenue	$	373.7	$	397	$	409.2

	Bristol-Myers Squibb Company
	Pursuant to commercial agreements with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), we are co-developing Erbitux in the U.S. and Canada with BMS through September 2018, exclusively, and in Japan with BMS and Merck through 2032. Under these arrangements, Erbitux research and development and other costs are shared by both companies according to a predetermined ratio.
	Responsibilities associated with clinical and other ongoing studies are apportioned between the parties under the agreements. Collaborative reimbursements received by us for supply of clinical trial materials; for research and development; and for a portion of marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated statement of operations. We receive a distribution fee in the form of a royalty from BMS, based on a percentage of net sales in the U.S. and Canada, which is recorded in collaboration and other revenue. Royalty expense paid to third parties, net of any reimbursements received, is recorded as a reduction of collaboration and other revenue.
	We are responsible for the manufacture and supply of all requirements of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in the U.S. and Canada, and BMS will purchase all of its requirements of API for commercial use from us, subject to certain stipulations per the agreement. Sales of Erbitux to BMS for commercial use are reported in net product sales.
	Merck KGaA
	A development and license agreement grants Merck exclusive rights to market Erbitux outside of the U.S. and Canada, and expires in December 2018. A separate agreement grants co-exclusive rights among Merck, BMS and us in Japan and expires in 2032.
	Merck manufactures Erbitux for supply in its territory as well as for Japan. We receive a royalty on the sales of Erbitux outside of the U.S. and Canada, which is included in collaboration and other revenue as earned. Collaborative reimbursements received for research and development and for marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated statement of operations. Royalty expense paid to third parties, net of any royalty reimbursements received, is recorded as a reduction of collaboration and other revenue.
	Diabetes Collaboration
	In January 2011, we and Boehringer Ingelheim entered into a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently, the compounds included in the collaboration are Boehringer Ingelheim's two oral diabetes agents, linagliptin and empagliflozin, and our new insulin glargine product. Additionally, Boehringer Ingelheim may elect to opt in to the Phase III development and potential commercialization of our anti-TGF-beta monoclonal antibody. Under the terms of the global agreement, we made an initial one-time payment to Boehringer Ingelheim of $388.0 million and recorded an acquired IPR&D charge, which was included as expense in the first quarter of 2011 and was deductible for tax purposes.
	Linagliptin was subsequently approved in 2011 and launched in the U.S. (trade name Tradjenta®), Japan (trade name TrazentaTM), certain countries in Europe (trade name Trajenta®), and other countries. Currently, empagliflozin and the new insulin glargine product are both under regulatory review in the U.S., Europe, and Japan, and the anti-TGF-beta monoclonal antibody is in Phase II clinical testing.
	In connection with the approval of linagliptin in the U.S., Japan, and Europe, in 2011 we paid $478.7 million in success-based regulatory milestones, all of which were capitalized as intangible assets and are being amortized to cost of sales. We incurred milestone-related expenses of $97.2 million in connection with regulatory submissions for empagliflozin in the U.S., Europe, and Japan during 2013. These regulatory submission milestones were recorded as research and development expenses. We may also pay up to 225.0 million euro in additional success-based regulatory milestones for empagliflozin.
	During 2013, we earned $50.0 million in milestones for the regulatory submissions of our new insulin glargine product in the U.S., Europe, and Japan. These submission milestones were recorded as income in other–net, (income) expense. In the future, we will be eligible to receive up to $250.0 million in success-based regulatory milestones on our new insulin glargine product.
	Should Boehringer Ingelheim elect to opt in to the Phase III development and potential commercialization of the anti-TGF-beta monoclonal antibody, we would be eligible for up to $525.0 million in opt-in and success-based regulatory milestone payments.
	The companies share ongoing development costs equally. The companies also share in the commercialization costs and gross margin for any product resulting from the collaboration that receives regulatory approval. We record our portion of the gross margin as collaboration and other revenue, and we record our portion of the commercialization costs as marketing, selling, and administrative expense. Each company will also be entitled to potential performance payments on sales of the molecules they contribute to the collaboration. Our revenue related to this collaboration (which is, to-date, entirely related to Trajenta) was $249.2 million, $88.6 million, and $15.1 million for the years ended December 31, 2013, 2012, and 2011, respectively.
	Solanezumab
	We have an agreement with an affiliate of TPG-Axon Capital (TPG) whereby TPG funded a portion of the Phase III development of solanezumab. Under the agreement, TPG’s obligation to fund solanezumab costs was not material and ended in the first half of 2011. In exchange for their funding, TPG may receive success-based sales milestones totaling approximately $70 million and mid-single digit royalties contingent upon the successful development of solanezumab. The royalties would be paid for approximately ten years after launch of a product.
	Baricitinib
	In December 2009, we entered into a worldwide license and collaboration agreement with Incyte Corporation (Incyte) to acquire development and commercialization rights to its Janus tyrosine kinase (JAK) inhibitor compound, now known as baricitinib, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. In 2010, Incyte exercised its option to co-develop baricitinib in rheumatoid arthritis. The agreement also provides Incyte with an option to co-promote in the U.S. and calls for payments associated with certain development, success-based regulatory, and sales-based milestones. Upon initiation of Phase III trials for the treatment of rheumatoid arthritis in the fourth quarter of 2012, we incurred a milestone-related expense of $50.0 million which was recorded as research and development expense. As of December 31, 2013, Incyte is eligible to receive up to $415.0 million of additional payments from us contingent upon certain development and success-based regulatory milestones as well as an additional $150.0 million of potential sales-based milestones.
	Tanezumab
	In October 2013, we entered into a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the potential treatment of osteoarthritis pain, chronic low back pain and cancer pain. Tanezumab is currently in Phase III development and is subject to a partial clinical hold by the FDA pending submission of nonclinical data to the FDA. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and commercialization expenses. Contingent upon the parties continuing in the collaboration after receipt of the FDA's response to the submission of the nonclinical data, we will be obligated to pay an upfront fee of $200.0 million. This payment would be immediately expensed. In addition to this fee, we may pay up to $350.0 million in success-based regulatory milestones and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab. Both parties have the right to terminate the agreement under certain circumstances.
	Summary of Collaboration-Related Commission and Profit-Share Payments
	The aggregate amount of commission and profit-share payments included in marketing, selling, and administrative expense pursuant to the collaborations described above was $203.7 million, $188.5 million, and $125.4 million for the years ended December 31, 2013, 2012, and 2011, respectively.

Asset_Impairments_Restructurin

Asset Impairments, Restructuring, and Other Special Charges	12 Months Ended
	Dec. 31, 2013
Extraordinary and Unusual Items [Abstract]	'
Asset Impairments, Restructuring, And Other Special Charges [Text Block]	'
	Note 5: Asset Impairment, Restructuring, and Other Special Charges
	The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below.


		2013		2012		2011
	Severance	$	90.6	$	74.5	$	251.8

	Asset impairment and other special charges	30		206.6		149.6

	Asset impairment, restructuring, and other special charges	$	120.6	$	281.1	$	401.4

	Severance costs listed above for all years relate to initiatives to reduce our cost structure and global workforce.
	For the year ended December 31, 2013, we incurred $30.0 million of asset impairment and other special charges related primarily to costs associated with the anticipated closure of a packaging and distribution facility in Germany.
	For the year ended December 31, 2012, we incurred $206.6 million of asset impairment and other special charges consisting of $122.6 million related to an intangible asset impairment for liprotamase (see Note 8) net of the reduction of the related contingent consideration liability, $64.0 million related to the recognition of an asset impairment associated with the decision to stop development of a delivery device platform, and $20.0 million resulting from a change in our estimates of returned product related to the withdrawal of Xigris™ from the market during the fourth quarter of 2011.
	For the year ended December 31, 2011, we incurred $149.6 million of asset impairments and other special charges primarily consisting of $85.0 million for returned product and contractual commitments related to the withdrawal of Xigris from the market and $56.1 million related to our decision to vacate certain leased premises.

Inventories_Notes

Inventories (Notes)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 6: Inventories
	Inventories at December 31 consisted of the following:


		2013			2012
	Finished products	$	968.1		$	834.4

	Work in process	1,868.30			1,735.80

	Raw materials and supplies	259			256.1

		3,095.40			2,826.30

	Reduction to LIFO cost	(166.6		)	(182.5		)
	Inventories	$	2,928.80		$	2,643.80

	Inventories valued under the LIFO method comprised $1.02 billion and $994.3 million of total inventories at December 31, 2013 and 2012, respectively.

Financial_Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Financial Instruments [Text Block]	'
	Note 7: Financial Instruments
	Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-sciences products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.
	At December 31, 2013, we had outstanding foreign currency forward commitments to purchase 462.6 million U.S. dollars and sell 337.6 million euro; commitments to purchase 520.7 million euro and sell 716.8 million U.S. dollars; commitments to purchase 180.7 million British pounds and sell 216.0 million euro; and commitments to purchase 234.4 million U.S. dollars and sell 24.35 billion Japanese yen, which will all settle within 30 days.
	At December 31, 2013, substantially all of our total debt is at a fixed rate. We have converted approximately 65 percent of our fixed-rate debt to floating rates through the use of interest rate swaps.
	During 2013 we entered into forward-starting interest rate swaps with a notional amount of $500.0 million and maturities not exceeding 30 years to hedge a portion of the cash flows associated with the planned refinancing of our $1.00 billion March 2014 debt maturity.
	The Effect of Risk Management Instruments on the Statement of Operations
	The following effects of risk-management instruments were recognized in other—net, (income) expense:


		2013				2012				2011
	Fair value hedges:
	Effect from hedged fixed-rate debt	$	(308.2	)		$	51.5			$	259.6

	Effect from interest rate contracts	308.2				(51.5		)		(259.6		)

	Cash flow hedges:
	Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	9				9				9

	Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments	15.4				(35.8		)		97.4


	The effective portion of net gains (losses) on equity contracts in designated cash flow hedging relationships recorded in other comprehensive income (loss) was $(149.6) million, $0.0 million, and $35.6 million for the years ended December 31, 2013, 2012, and 2011, respectively. There were no equity contracts in designated cash flow hedging relationships in 2012. During the next 12 months, we expect to sell the underlying equity securities in designated cash flow hedging relationships that were outstanding at December 31, 2013, and will reclassify to earnings the accumulated other comprehensive loss related to the cash flow hedges and the unrealized gains on the underlying equity securities. The unrealized gains are in excess of the losses on the cash flow hedges.
	For forward-starting interest rate swaps in designated cash flow hedging relationships associated with an anticipated debt issuance, the effective portion of net gains recorded in other comprehensive income (loss) was $16.7 million for the year ended December 31, 2013. There were no forward-starting interest rate swaps in designated cash flow hedging relationships in 2012 and 2011.
	During the next 12 months, we expect to reclassify from accumulated other comprehensive loss to earnings $8.8 million of pretax net losses on cash flow hedges of the variability in expected future interest payments on our floating rate debt.
	During the years ended December 31, 2013, 2012, and 2011, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.
	Fair Value of Financial Instruments
	The following tables summarize certain fair value information at December 31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:


										Fair Value Measurements Using
	Description	Carrying				Amortized				Quoted Prices in Active Markets for Identical Assets				Significant			Significant		Fair
		Amount				Cost				(Level 1)				Other			Unobservable		Value
														Observable			Inputs
														Inputs			(Level 3)
														(Level 2)
	31-Dec-13
	Cash and cash equivalents	$	3,830.20			$	3,830.20			$	3,772.60			$	57.6		$		$	3,830.20

	Short-term investments:
	U.S. government and agencies	$	276.4			$	276.6			$	276.4			$			$		$	276.4

	Corporate debt securities	931.7				929.8								931.7					931.7

	Other securities	2.7				2.7								2.7					2.7

	Marketable equity	356.3				75				356.3									356.3

	Short-term investments	$	1,567.10			$	1,284.10

	Noncurrent investments:
	U.S. government and agencies	$	1,115.60			$	1,126.10			$	1,035.60			$	80		$		$	1,115.60

	Corporate debt securities	4,940.50				4,933.70								4,940.50					4,940.50

	Mortgage-backed	636				652.4								636					636

	Asset-backed	490				494.5								490					490

	Other securities	7.3				8.3								7.3					7.3

	Marketable equity	81.2				22.8				81.2									81.2

	Equity method and other investments(1)	354.3				354.3

Noncurrent investments	$	7,624.90			$	7,592.10


31-Dec-12
Cash and cash equivalents	$	4,018.80			$	4,018.80			$	3,964.40			$	54.4		$		$	4,018.80

Short-term investments:
U.S. government and agencies	$	150.2			$	150.2			$	150.2			$			$		$	150.2

Corporate debt securities	1,503.50				1,501.50								1,503.50					1,503.50

Other securities	11.8				11.8								11.8					11.8

Short-term investments	$	1,665.50			$	1,663.50

Noncurrent investments:
U.S. government and agencies	$	1,362.70			$	1,360.30			$	1,122.40			$	240.3		$		$	1,362.70

Corporate debt securities	3,351.30				3,322.90								3,351.30					3,351.30

Mortgage-backed	668.1				677.7								668.1					668.1

Asset-backed	519				523.5								519					519

Other securities	3.3				3.3								3.3					3.3

Marketable equity	175.8				83				175.8									175.8

Equity method and other investments(1)	233.7				233.7

Noncurrent investments	$	6,313.90			$	6,204.40


1	Fair value not applicable


					Fair Value Measurements Using
Description	Carrying				Quoted Prices in Active Markets for Identical Assets		Significant				Significant		Fair
	Amount				(Level 1)		Other				Unobservable		Value
							Observable				Inputs
							Inputs				(Level 3)
							(Level 2)
Long-term debt, including current portion
December 31, 2013	$	(5,212.9	)		$		$	(5,490.9	)		$		$	(5,490.9	)
31-Dec-12	(5,531.3		)				(5,996.6		)				(5,996.6		)




					Fair Value Measurements Using
Description	Carrying				Quoted Prices in Active Markets for Identical Assets		Significant				Significant		Fair
	Amount				(Level 1)		Other				Unobservable		Value
							Observable				Inputs
							Inputs				(Level 3)
							(Level 2)
31-Dec-13
Risk-management instruments
Interest rate contracts designated as hedging instruments:
Other receivables	$	20.1			$		$	20.1			$		$	20.1

Sundry	278.7						278.7						278.7

Other noncurrent liabilities	(0.9		)				(0.9		)				(0.9		)
Foreign exchange contracts not designated as hedging instruments:
Other receivables	6.7						6.7						6.7

Other current liabilities	(7.1		)				(7.1		)				(7.1		)
Equity contracts designated as hedging instruments:
Other current liabilities	(149.6		)				(149.6		)				(149.6		)

31-Dec-12
Risk-management instruments
Interest rate contracts designated as hedging instruments:
Sundry	589.4						589.4						589.4

Foreign exchange contracts not designated as hedging instruments:
Other receivables	11						11						11

Other current liabilities	(17.5		)				(17.5		)				(17.5		)
Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to an enforceable master netting arrangement or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material.
We determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. The fair value of equity method investments and other investments is not readily available.
The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2013:


	Maturities by Period
	Total				Less Than				5-Jan				10-Jun			More Than
					1 Year				Years				Years			10 Years
Fair value of debt securities	$	8,400.20			$	1,210.80			$	5,977.40			$	471.3		$	740.7


A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:


	2013				2012
Unrealized gross gains	$	375.6			$	140.5

Unrealized gross losses	59.8				29

Fair value of securities in an unrealized gain position	4,982.70				5,246.00

Fair value of securities in an unrealized loss position	3,664.70				2,102.00

Other-than-temporary impairment losses on investment securities of $11.3 million, $22.6 million, and $31.1 million were recognized in the consolidated statements of operations for the years ended December 31, 2013, 2012, and 2011, respectively. For fixed-income securities, the amount of credit losses represents the difference between the present value of cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing the credit loss were the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.
The securities in an unrealized loss position include fixed-rate debt securities of varying maturities. The value of fixed-income securities is sensitive to changes in the yield curve and other market conditions. Approximately 90 percent of the securities in a loss position are investment-grade debt securities. At this time, there is no indication of default on interest or principal payments for debt securities other than those for which an other-than-temporary impairment charge has been recorded. We do not intend to sell and it is not more likely than not we will be required to sell the securities in a loss position before the market values recover or the underlying cash flows have been received, and we have concluded that no additional other-than-temporary loss is required to be charged to earnings as of December 31, 2013.
Activity related to our investment portfolio, substantially all of which related to available-for-sale securities, was as follows:


	2013				2012				2011
Proceeds from sales	$	13,753.50			$	6,529.80			$	2,268.30

Realized gross gains on sales	49.5				82.3				140

Realized gross losses on sales	15.4				10.9				9.9

Goodwill_and_Other_Intangibles

Goodwill and Other Intangibles	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	Note 8: Goodwill and Other Intangibles
	Goodwill and other indefinite-lived intangible assets at December 31 were as follows:


		2013		2012
	Goodwill (by segment):
	Human pharmaceutical products	$	1,354.70	$	1,364.20

	Animal health	162.1		137.1

	Total goodwill	1,516.80		1,501.30

	In-process research and development	33.6		65

	Total indefinite-lived intangible assets	$	1,550.40	$	1,566.30

	No impairments occurred with respect to the carrying value of goodwill for the years ended December 31, 2013, 2012, and 2011.
	IPR&D consists of the acquisition date fair value of products under development acquired in business combinations that have not yet achieved regulatory approval for marketing adjusted for subsequent impairments. Examples of such products acquired in business combinations include liprotamase and Amyvid®, which are discussed further below. As discussed in Note 1, we use the "income method" to calculate the fair value of the IPR&D assets, which is a Level 3 fair value measurement.
	No material impairments occurred with respect to the carrying value of IPR&D for the year ended December 31, 2013.
	In 2012, we recorded impairment charges of $205.0 million related to liprotamase as a result of changes in key assumptions used in the valuation, based upon additional communications with the FDA regarding the clinical trial that would be required for resubmission, and our expectations for the product.
	In 2011, we recorded impairment charges of $151.5 million due primarily to the impairment of the IPR&D assets related to Amyvid and liprotamase. The impairment of Amyvid was due to a delay in product launch and lower sales projections during the early part of the product’s expected life cycle. In April 2011, we received a complete response letter from the FDA for the New Drug Application (NDA) for liprotamase, which communicated the need for us to conduct an additional clinical trial prior to a resubmission, resulting in an impairment of liprotamase.
	The components of finite-lived intangible assets at December 31 were as follows:


		2013							2012
	Description	Carrying		Accumulated			Carrying		Carrying		Accumulated			Carrying
		Amount—		Amortization			Amount—		Amount—		Amortization			Amount—
		Gross					Net		Gross					Net
	Marketed products	$	5,136.10	$	(2,447.2	)	$	2,688.90	$	5,107.90	$	(1,987.0	)	$	3,120.90

	Other	164.8		(73.0		)	91.8		129.5		(64.0		)	65.5

	Total finite-lived intangible assets	$	5,300.90	$	(2,520.2	)	$	2,780.70	$	5,237.40	$	(2,051.0	)	$	3,186.40

	Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. Other intangibles consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. No material impairments occurred with respect to the carrying value of finite-lived intangible assets for the years ended December 31, 2013, 2012 and 2011.
	See Note 3 for further discussion of intangible assets acquired in recent business combinations.
	As of December 31, 2013, the remaining weighted-average amortization period for finite-lived intangible assets is approximately 8 years. Amortization expense was $555.0 million, $563.0 million, and $469.0 million for 2013, 2012, and 2011, respectively. The estimated amortization expense associated with our current finite-lived intangible assets for each of the next five years approximates $530 million in 2014, $490 million in 2015, $380 million in 2016, $200 million in 2017, and $180 million in 2018. Amortization expense is included in either cost of sales, marketing, selling, and administrative or research and development depending on the nature of the intangible asset being amortized.

Property_and_Equipment_Notes

Property and Equipment (Notes)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 9: Property and Equipment
	At December 31, property and equipment consisted of the following:


		2013			2012
	Land	$	198.7		$	201.4

	Buildings	6,489.90			6,373.80

	Equipment	7,752.70			7,542.90

	Construction in progress	1,205.40			799.9

		15,646.70			14,918.00

	Less accumulated depreciation	(7,671.2		)	(7,157.8		)
	Property and equipment, net	$	7,975.50		$	7,760.20

	Depreciation expense for the years ended December 31, 2013, 2012, and 2011 was $774.8 million, $754.0 million, and $732.4 million, respectively. Interest costs of $24.1 million, $21.0 million, and $25.7 million were capitalized as part of property and equipment for the years ended December 31, 2013, 2012, and 2011, respectively. Total rental expense for all leases, including contingent rentals (not material), amounted to $227.2 million, $262.2 million, and $267.4 million for the years ended December 31, 2013, 2012, and 2011, respectively. Assets under capital leases included in property and equipment, net on the consolidated balance sheets, capital lease obligations entered into, and future minimum rental commitments are not material.

Borrowings

Borrowings	12 Months Ended
	Dec. 31, 2013
Long-term Debt, Current and Noncurrent [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 10: Borrowings
	Long-term debt at December 31 consisted of the following:


		2013			2012
	4.20 to 7.13 percent notes (due 2014-2037)	$	4,887.30		$	4,887.30

	Other, including capitalized leases	27.1			37.4

	Fair value adjustment	298.5			606.6

		5,212.90			5,531.30

	Less current portion	(1,012.6		)	(11.9		)
	Long-term debt	$	4,200.30		$	5,519.40

	Current maturities of long-term debt of $1.51 billion were repaid during the year ended December 31, 2012.
	The aggregate amounts of maturities on long-term debt for the next five years are $1.01 billion in 2014, $9.5 million in 2015, $205.6 million in 2016, $1.00 billion in 2017, and $200.3 million in 2018.
	At December 31, 2013, we have $1.36 billion of unused committed bank credit facilities, $1.20 billion of which is a revolving credit facility that backs our commercial paper program and matures in April 2015. There were no amounts outstanding under the revolving credit facility during the year ended December 31, 2013. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn.
	We have converted approximately 65 percent of all fixed-rate debt to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on debt obligations and interest rates at December 31, 2013 and 2012, including the effects of interest rate swaps for hedged debt obligations, were 3.10 percent and 3.20 percent, respectively.
	For the years ended December 31, 2013, 2012, and 2011, cash payments for interest on borrowings totaled $139.7 million, $171.9 million, and $167.4 million, respectively, net of capitalized interest.
	In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged, as a fair value hedge, is reflected in the consolidated balance sheets as an amount equal to the sum of the debt’s carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2013
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]	'
Stock-Based Compensation [Text Block]	'
	Note 11: Stock-Based Compensation
	Stock-based compensation expense of $144.9 million, $141.5 million, and $147.4 million was recognized for the years ended December 31, 2013, 2012, and 2011, respectively, as well as related tax benefits of $50.7 million, $49.5 million, and $51.6 million, respectively. Our stock-based compensation expense consists of performance awards (PAs), shareholder value awards (SVAs), and restricted stock units (RSUs). We recognize stock-based compensation expense over the requisite service period of the individual grantees, which equals the vesting period. We provide newly issued shares and treasury stock to satisfy stock option exercises and for the issuance of PA, SVA, and RSU shares. We classify tax benefits resulting from tax deductions in excess of the compensation cost recognized for exercised stock options as a financing cash flow in the consolidated statements of cash flows.
	At December 31, 2013, additional stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 100.0 million shares.
	Performance Award Program
	PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement periods. The fair values of PAs granted for the years ended December 31, 2013, 2012, and 2011 were $50.19, $35.74, and $31.90, respectively. The number of shares ultimately issued for the PA program is dependent upon the earnings achieved during the vesting period. Pursuant to this plan, approximately 0.7 million shares, 1.6 million shares, and 3.9 million shares were issued during the years ended December 31, 2013, 2012, and 2011, respectively. Approximately 0.6 million shares are expected to be issued in 2014. As of December 31, 2013, the total remaining unrecognized compensation cost related to nonvested PAs was $18.9 million, which will be amortized over the weighted-average remaining requisite service period of 12 months.
	Shareholder Value Award Program
	SVAs are granted to officers and management and are payable in shares of our common stock at the end of a three-year period. The number of shares actually issued, if any, varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December 31, 2013, 2012, and 2011 were $45.17, $30.35, and $28.33, respectively, determined using the following assumptions:


	(Percents)	2013		2012		2011
	Expected dividend yield	3.5	%	4.5	%	4.9	%
	Risk-free interest rate	.08-.43		.10-.36		.20-1.36

	Range of volatilities	18.95-22.37		22.40-25.64		27.61-29.10

	A summary of the SVA activity is presented below:


	Units Attributable to SVAs (in thousands)	2013		2012		2011
	Outstanding at January 1	7,539		7,036		6,381

	Granted	1,795		2,439		2,561

	Issued	(2,397	)	(973	)	(428	)
	Forfeited or expired	(301	)	(963	)	(1,478	)
	Outstanding at December 31	6,636		7,539		7,036

	Approximately 2.2 million shares are expected to be issued in 2014. As of December 31, 2013, the total remaining unrecognized compensation cost related to nonvested SVAs was $51.6 million, which will be amortized over the weighted-average remaining requisite service period of 20 months.
	Restricted Stock Units
	RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically 3 years. The fair values of RSU awards granted during the years ended December 31, 2013, 2012, and 2011 were $54.10, $39.65, and $35.80, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this plan, 1.1 million, 1.4 million, and 1.5 million shares were granted during the years ended December 31, 2013, 2012, and 2011, respectively, and approximately 0.8 million, 0.3 million, and 0.2 million shares were issued during the years ended December 31, 2013, 2012, and 2011, respectively. Approximately 0.8 million shares are expected to be issued in 2014. As of December 31, 2013, the total remaining unrecognized compensation cost related to nonvested RSUs was $58.4 million, which will be amortized over the weighted-average remaining requisite service period of 21 months.
	Stock Option Program
	Stock options were granted prior to 2007 to officers, management, and board members at exercise prices equal to the fair market value of our stock at the date of grant. Options fully vested 3 years from the grant date and have a term of 10 years.
	Stock option activity during the year ended December 31, 2013 is summarized below:


		Shares of		Weighted-Average			Weighted-Average	Aggregate
		Common Stock		Exercise			Remaining	Intrinsic
		Attributable to		Price of Options			Contractual Term	Value
		Options					(in years)
		(in thousands)
	Outstanding at January 1, 2013	27,232		$	63.89

	Exercised	(208	)	54.27

	Forfeited or expired	(10,884	)	59.95

	Outstanding at December 31, 2013	16,140		66.66			0.7	$	—

	Exercisable at December 31, 2013	16,140		66.66			0.7	—

	For options exercised during the years ended December 31, 2013, 2012, and 2011, the related intrinsic value, cash received, and tax benefits were not material.

Shareholders_Equity

Shareholders' Equity	12 Months Ended
Shareholders' Equity	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Shareholders' Equity [Text Block]	'
	Note 12: Shareholders' Equity
	During 2013, we purchased $500.0 million of shares associated with our $5.00 billion share repurchase program that was announced in the fourth quarter of 2013. As of December 31, 2013, there were $4.50 billion of shares remaining in that program. During 2013 and 2012, we repurchased $1.10 billion and $400.0 million, respectively, of shares, completing our $1.50 billion share repurchase program announced in 2012. During 2012, we also repurchased $419.2 million of shares, completing our $3.00 billion share repurchase program announced in 2000. No shares were repurchased during the year ended December 31, 2011.
	We have 5.0 million authorized shares of preferred stock. As of December 31, 2013 and 2012, no preferred stock has been issued.
	We have an employee benefit trust that held 50.0 million shares of our common stock at both December 31, 2013 and 2012, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01 billion at both December 31, 2013 and 2012, and is shown as a reduction in shareholders’ equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of earnings per share. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December 31, 2013, 2012, and 2011.
	We have an ESOP as a funding vehicle for the existing employee savings plan. The ESOP used the proceeds of a loan from us to purchase shares of common stock from our treasury. The ESOP issued third-party debt, which was repaid in 2011. The proceeds were used to purchase shares of our common stock on the open market. As of December 31, 2013, all shares of common stock held by the ESOP were allocated to participating employees as part of our savings plan contribution. The fair value of shares allocated each period was recognized as compensation expense.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 13: Earnings Per Share
	Following is a reconciliation of the denominators used in computing earnings per share:


	(Shares in thousands)	2013		2012		2011
	Income available to common shareholders	$	4,684.80	$	4,088.60	$	4,347.70

	Basic earnings per share:

	Weighted-average number of common shares outstanding, including incremental shares	1,080,874		1,113,178		1,113,923

	Basic earnings per share	$	4.33	$	3.67	$	3.9

	Diluted earnings per share:

	Weighted-average number of common shares outstanding, including incremental shares and stock options	1,084,766		1,117,294		1,113,967

	Diluted earnings per share	$	4.32	$	3.66	$	3.9

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes [Text Block]	'
	Note 14: Income Taxes
	Following is the composition of income tax expense:


		2013				2012				2011
	Current:
	Federal	$	259.1			$	596.8			$	671.4

	Foreign	553.2				540.6				759.5

	State	126.3				56.2				(22.9		)

	Total current tax expense	938.6				1,193.60				1,408.00

	Deferred:
	Federal	297				87				(398.5		)

	Foreign	(28.2		)		29.9				(34.7		)

	State	(2.9		)		9.1				27

	Total deferred tax expense (benefit)	265.9				126				(406.2		)

	Income taxes	$	1,204.50			$	1,319.60			$	1,001.80

	Significant components of our deferred tax assets and liabilities as of December 31 are as follows:


		2013				2012
	Deferred tax assets:
	Compensation and benefits	$	639.8			$	1,081.80

	Tax credit carryforwards and carrybacks	494.6				703.2

	Purchases of intangible assets	418.8				366.8

	Product return reserves	313.7				153.8

	Tax loss carryforwards and carrybacks	311.7				370.1

	Debt	110				232.8

	Contingencies	106				113.2

	Intercompany profit in inventories	104.5				159.6

	Sale of intangibles	76.5				278.6

	Other	518.5				361.5

	Total gross deferred tax assets	3,094.10				3,821.40

	Valuation allowances	(647.1		)		(675.8		)
	Total deferred tax assets	2,447.00				3,145.60

	Deferred tax liabilities:
	Unremitted earnings	(898.3		)		(920.4		)
	Inventories	(685.6		)		(573.4		)
	Intangibles	(598.9		)		(708.8		)
	Prepaid employee benefits	(446.2		)		—

	Property and equipment	(379.1		)		(407.1		)
	Financial instruments	(109.6		)		(257.0		)
Total deferred tax liabilities	(3,117.7		)		(2,866.7		)
Deferred tax assets (liabilities) - net	$	(670.7	)		$	278.9

At December 31, 2013 and 2012, no individually significant items were classified as “Other” deferred tax assets.
The deferred tax asset and related valuation allowance amounts for U.S. federal and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.
Based on filed tax returns, we have tax credit carryforwards and carrybacks of $494.6 million available to reduce future income taxes; $2.9 million will be carried back; $183.8 million of the tax credit carryforwards will expire between 2023 and 2033; and $4.9 million of the tax credit carryforwards will never expire. The remaining portion of the tax credit carryforwards is related to federal tax credits of $80.3 million, international tax credits of $105.3 million, and state tax credits of $117.4 million, all of which are substantially reserved.
At December 31, 2013, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. income tax purposes of $662.5 million: $262.8 million will expire by 2018; $356.8 million will expire between 2018 and 2033; and $42.9 million of the carryforwards will never expire. Other carryforwards for international and U.S. federal income tax purposes are substantially reserved. Deferred tax assets related to state net operating losses of $81.0 million and $9.8 million of other state carryforwards are substantially reserved.
Domestic and Puerto Rican companies contributed approximately 61 percent, 54 percent, and 24 percent for the years ended December 31, 2013, 2012, and 2011, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant. The current tax incentive grant will not expire prior to 2017.
At December 31, 2013, U.S. income taxes have not been provided on approximately $23.74 billion of unremitted earnings of foreign subsidiaries as we consider these unremitted earnings to be indefinitely invested for continued use in our foreign operations. Additional tax provisions will be required if these earnings are repatriated in the future to the United States. Due to complexities in the tax laws and assumptions that we would have to make, it is not practicable to determine the amount of the related unrecognized deferred income tax liability.
Cash payments of income taxes totaled $1.26 billion, $992.0 million, and $942.8 million, for the years ended December 31, 2013, 2012, and 2011, respectively.
Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:


	2013				2012				2011
Income tax at the U.S. federal statutory tax rate	$	2,061.30			$	1,892.90			$	1,872.30

Add (deduct):
International operations, including Puerto Rico	(778.3		)		(593.8		)		(796.7		)
General business credits	(175.6		)		(11.2		)		(80.8		)
IRS audit conclusion	(7.9		)		—				(85.3		)

Other	105				31.7				92.3

Income taxes	$	1,204.50			$	1,319.60			$	1,001.80

The American Taxpayer Relief Act of 2012, which included the reinstatement of the research tax credit for the year 2012, was enacted in early 2013. Therefore, the research tax credits for the years 2012 and 2013 are both included in 2013 with general business credits.
A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:


	2013				2012				2011
Beginning balance at January 1	$	1,534.30			$	1,369.30			$	1,714.30

Additions based on tax positions related to the current year	142.5				144.8				89.4

Additions for tax positions of prior years	251.5				70.1				390

Reductions for tax positions of prior years	(358.2		)		(38.5		)		(492.3		)
Settlements	(404.9		)		(9.2		)		(326.3		)
Lapses of statutes of limitation	(24.9		)		(4.6		)		(2.6		)
Changes related to the impact of foreign currency translation	(3.9		)		2.4				(3.2		)

Ending balance at December 31	$	1,136.40			$	1,534.30			$	1,369.30

The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $523.3 million and $928.1 million at December 31, 2013 and 2012, respectively.
We file income tax returns in the U.S. federal jurisdiction and various state, local, and non-U.S. jurisdictions. We are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations in most major taxing jurisdictions for years before 2007.
During 2011, we settled the U.S. examinations of tax years 2005-2007, along with certain matters related to tax years 2008-2009. The examination of the remainder of 2008-2009 commenced in the fourth quarter of 2011. Considering this current examination cycle, as well as the settlement of 2005-2007 and certain matters related to 2008-2009, our consolidated results of operations benefited from a reduction in tax expense of $85.3 million in 2011. We made cash payments totaling approximately $300 million for tax years 2005-2007.
During 2013, we reached resolution on the remaining matters related to tax years 2008–2009 that were not settled as part of a previous examination. Considering the impact of this resolution on periods that have not yet been examined, as well as its impact on tax asset carryforwards, there was an immaterial benefit to our consolidated results of operations. We made cash payments of approximately $135 million related to tax years 2008–2009 after application of available tax credit carryforwards and carrybacks. The examination of tax years 2010-2012 commenced during the fourth quarter of 2013. Because the examination of tax years 2010-2012 is still in the early stages, the resolution of matters in this audit period will likely extend beyond the next 12 months.
We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. During the years ended December 31, 2013, 2012, and 2011, we recognized income tax expense (benefit) of $(10.9) million, $42.3 million, and $(47.3) million, respectively, related to interest and penalties. At December 31, 2013 and 2012, our accruals for the payment of interest and penalties totaled $161.5 million and $187.5 million, respectively.

Retirement_Benefits

Retirement Benefits	12 Months Ended
	Dec. 31, 2013
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]	'
Retirement Benefits [Text Block]	'
	Note 15: Retirement Benefits
	We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows:


		Defined Benefit								Retiree Health
		Pension Plans								Benefit Plans
		2013				2012				2013				2012
	Change in benefit obligation:
	Benefit obligation at beginning of year	$	10,423.80			$	9,191.20			$	2,337.70			$	2,308.60

	Service cost	287.1				253.1				49.9				63.3

	Interest cost	437.2				455.1				98.1				114.9

	Actuarial (gain) loss	(792.2		)		834				(642.5		)		(57.0		)

	Benefits paid	(402.3		)		(404.2		)		(79.6		)		(67.2		)
	Plan amendments	(0.1		)		(0.6		)		(4.1		)		(28.4		)
	Foreign currency exchange rate changes and other adjustments	22.9				95.2				(2.3		)		3.5

	Benefit obligation at end of year	9,976.40				10,423.80				1,757.20				2,337.70



	Change in plan assets:
	Fair value of plan assets at beginning of year	8,286.60			7,186.30			1,518.00			1,339.00

	Actual return on plan assets	1,144.60			922.7			365.7			183.4

	Employer contribution	428.9			469.7			75.5			62.8

	Benefits paid	(402.3	)		(404.2	)		(79.6	)		(67.2	)
	Foreign currency exchange rate changes and other adjustments	23.9			112.1			—			—

	Fair value of plan assets at end of year	9,481.70			8,286.60			1,879.60			1,518.00



	Funded status	(494.7		)		(2,137.2		)		122.4				(819.7		)

	Unrecognized net actuarial loss	3,546.30				5,187.50				178.1				1,156.70

	Unrecognized prior service (benefit) cost	50.7				54.9				(171.5		)		(203.4		)

	Net amount recognized	$	3,102.30			$	3,105.20			$	129			$	133.6



	Amounts recognized in the consolidated balance sheet consisted of:
	Sundry	$	881.2			$	125.5			$	366.4			$	—

	Other current liabilities	(62.8		)		(61.2		)		(7.7		)		(8.9		)
	Accrued retirement benefits	(1,313.1		)		(2,201.6		)		(236.3		)		(810.8		)
	Accumulated other comprehensive loss before income taxes	3,597.00				5,242.50				6.6				953.3

	Net amount recognized	$	3,102.30			$	3,105.20			$	129			$	133.6

	The unrecognized net actuarial loss and unrecognized prior service cost (benefit) have not yet been recognized in net periodic pension costs and are included in accumulated other comprehensive loss at December 31, 2013.
	During 2014, we expect the following components of accumulated other comprehensive loss to be recognized as components of net periodic benefit cost:


		Defined Benefit				Retiree Health
		Pension Plans				Benefit Plans
Unrecognized net actuarial loss	$	277.2			$	20

Unrecognized prior service cost	3.6				(31.2		)

Total	$	280.8			$	(11.2	)

We do not expect any plan assets to be returned to us in 2014.
The following represents our weighted-average assumptions as of December 31:


	Defined Benefit						Retiree Health
	Pension Plans						Benefit Plans
(Percents)	2013		2012		2011		2013		2012		2011
Discount rate for benefit obligation	4.9		4.3		5		5		4.3		5.1
Discount rate for net benefit costs	4.3		5		5.6		4.3		5.1		5.8
Rate of compensation increase for benefit obligation	3.4		3.4		3.7
Rate of compensation increase for net benefit costs	3.4		3.7		3.7
Expected return on plan assets for net benefit costs	8.4		8.4		8.5		8.8		8.8		8.8
We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. Health-care-cost trend rates are assumed to increase at an annual rate of 6.6 percent for the year ended December 31, 2014, decreasing by approximately 0.3 percent per year to an ultimate rate of 5.0 percent by 2020.
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:


	2014				2015				2016				2017				2018			2019-2023
Defined benefit pension plans	$	430.9			$	440.1			$	453			$	469			$	486		$	2,726.00


Retiree health benefit plans-gross	$	94			$	98			$	102.3			$	106.4			$	111		$	612.3

Medicare rebates	(6.8		)		(7.6		)		(8.2		)		(9.0		)		(9.8		)	(60.5		)
Retiree health benefit plans-net	$	87.2			$	90.4			$	94.1			$	97.4			$	101.2		$	551.8

Amounts relating to defined benefit plans with projected benefit obligations in excess of plan assets were as follows at December 31:


	2013				2012
Projected benefit obligation	$	1,773.60			$	9,151.20

Fair value of plan assets	395.4				6,888.60

Amounts relating to defined benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:


	2013				2012
Accumulated benefit obligation	$	1,384.60			$	8,021.00

Fair value of plan assets	181.8				6,580.60

The total accumulated benefit obligation for our defined benefit pension plans was $9.13 billion and $9.46 billion at December 31, 2013 and 2012, respectively.
Net pension and retiree health benefit expense included the following components:


	Defined Benefit												Retiree Health
	Pension Plans												Benefit Plans
	2013				2012				2011				2013				2012			2011
Components of net periodic benefit cost:
Service cost	$	287.1			$	253.1			$	236.3			$	49.9			$	63.3		$	72.4

Interest cost	437.2				455.1				447.9				98.1				114.9			118

Expected return on plan assets	(701.9		)		(684.8		)		(685.9		)		(130.7		)		(127.2		)	(129.4		)
Amortization of prior service (benefit) cost	3.7				4.2				8.6				(35.6		)		(39.8		)	(42.9		)

Recognized actuarial loss	414.7				285.7				200.4				100.5				98.4			88.7

Net periodic benefit cost	$	440.8			$	313.3			$	207.3			$	82.2			$	109.6		$	106.8

If the healthcare-cost trend rates were to be increased by one percentage point, the December 31, 2013, accumulated postretirement benefit obligation would increase by $169.7 million and the aggregate of the service cost and interest cost components of the 2013 annual expense would increase by $9.4 million. A one percentage point decrease in these rates would decrease the December 31, 2013, accumulated postretirement benefit obligation by $149.1 million, and the aggregate of the 2013 service cost and interest cost by $7.6 million.
The following represents the amounts recognized in other comprehensive income (loss) for the year ended December 31, 2013:


	Defined Benefit				Retiree Health
	Pension Plans				Benefit Plans
Actuarial gain arising during period	$	1,234.70			$	877.6

Plan amendments during period	0.1				4.1

Amortization of prior service (benefit) cost included in net income	3.7				(35.6		)

Amortization of net actuarial loss included in net income	414.7				100.5

Foreign currency exchange rate changes	(7.7		)		0.1

Total other comprehensive income during period	$	1,645.50			$	946.7

We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plans are based on employee contributions and the level of our match. Expenses under the plans totaled $147.7 million, $136.3 million, and $124.8 million for the years ended December 31, 2013, 2012, and 2011, respectively.
We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December 31, 2013, 2012, and 2011 were not material.
Benefit Plan Investments
Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent 80 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.
We manage our portfolio to minimize any concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.
Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.
The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 80 percent growth investments and 20 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.
Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.
Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, mortgage-backed securities, and commercial mortgage-backed obligations.
Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests primarily in fund-of-funds structures to ensure diversification across many strategies and many individual managers. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.
Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, and special situation investing. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.
Real estate is composed of both public and private holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as Level 3. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.
Other assets include cash and cash equivalents and mark-to-market value of derivatives.
The cash value of the trust-owned insurance contract is invested in investment-grade publicly traded equity and fixed-income securities.
Other than hedge funds, private equity-like investments, and real estate, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.
The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2013 by asset category are as follows:


					Fair Value Measurements Using
Asset Class	Total				Quoted Prices in Active Markets for				Significant				Significant
					Identical Assets				Observable Inputs				Unobservable Inputs
					(Level 1)				(Level 2)				(Level 3)
Defined Benefit Pension Plans
Public equity securities:
U.S.	$	400.3			$	189.2			$	211.1			$

International	2,483.80				1,045.80				1,438.00

Fixed income:
Developed markets	1,036.10				170.2				850				15.9

Emerging markets	382.6								382.6

Private alternative investments:
Hedge funds	2,902.30								1,461.90				1,440.40

Equity-like funds	1,069.90								76.4				993.5

Real estate	521.4				368								153.4

Other	685.3				245.2				440.1

Total	$	9,481.70			$	2,018.40			$	4,860.10			$	2,603.20

Retiree Health Benefit Plans
Public equity securities:
U.S.	$	39.4			$	18.3			$	21.1			$

International	167.2				61.6				105.6

Fixed income:
Developed markets	54.7								53.1				1.6

Emerging markets	38.2								38.2

Private alternative investments:
Hedge funds	266.4								145.8				120.6

Equity-like funds	88.9												88.9

Cash value of trust owned insurance contract	1,136.80								1,136.80

Real estate	36.7				36.7

Other	51.3				18				33.3

Total	$	1,879.60			$	134.6			$	1,533.90			$	211.1

No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2013.
The activity in the Level 3 investments during the year ended December 31, 2013 was as follows:


	Fixed Income: Developed Markets				Hedge				Equity-like				Real				Total
					Funds				Funds				Estate
Defined Benefit Pension Plans
Beginning balance at January 1, 2013	$	3.7			$	1,218.10			$	910.5			$	142.6			$	2,274.90

Actual return on plan assets, including changes in foreign exchange rates:
Relating to assets still held at the reporting date	(3.0		)		123.4				155.7				8.5				284.6

Relating to assets sold during the period	—				—				—				—				—

Purchases, sales, and settlements, net	3.7				98.9				(72.7		)		2.3				32.2

Transfers into (out of) Level 3	11.5				—				—				—				11.5

Ending balance at December 31, 2013	$	15.9			$	1,440.40			$	993.5			$	153.4			$	2,603.20

Retiree Health Benefit Plans
Beginning balance at January 1, 2013	$	0.4			$	99.9			$	81.9							$	182.2

Actual return on plan assets, including changes in foreign exchange rates:
Relating to assets still held at the reporting date	(0.3		)		10.3				13.9								23.9

Relating to assets sold during the period	—				—				—								—

Purchases, sales, and settlements, net	0.4				10.4				(6.9		)						3.9

Transfers into (out of) Level 3	1.1				—				—								1.1

Ending balance at December 31, 2013	$	1.6			$	120.6			$	88.9							$	211.1

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2012 by asset category are as follows:


					Fair Value Measurements Using
Asset Class	Total				Quoted Prices in Active Markets for Identical Assets				Significant Observable Inputs				Significant Unobservable Inputs
					(Level 1)				(Level 2)				(Level 3)
Defined Benefit Pension Plans
Public equity securities:
U.S.	$	457.7			$	307.9			$	149.8			$

International	1,905.30				673.3				1,232.00

Fixed income:
Developed markets	1,075.40				156.4				915.3				3.7

Emerging markets	402.3								402.3

Private alternative investments:
Hedge funds	2,555.50								1,337.40				1,218.10

Equity-like funds	991.2				17.4				63.3				910.5

Real estate	504.3				353.5				8.2				142.6

Other	394.9				140.1				254.8

Total	$	8,286.60			$	1,648.60			$	4,363.10			$	2,274.90

Retiree Health Benefit Plans
Public equity securities:
U.S.	$	45.4			$	30.4			$	15			$

International	127.7				33.9				93.8

Fixed income:
Developed markets	59.4								59				0.4

Emerging markets	40.3								40.3

Private alternative investments:
Hedge funds	234								134.1				99.9

Equity-like funds	81.9												81.9

Cash value of trust owned insurance contract	869.1								869.1

Real estate	35.4				35.4

Other	24.8				6.2				18.6

Total	$	1,518.00			$	105.9			$	1,229.90			$	182.2

No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2012.
The activity in the Level 3 investments during the year ended December 31, 2012 was as follows:


	Fixed Income: Developed Markets				Hedge				Equity-like				Real				Total
					Funds				Funds				Estate
Defined Benefit Pension Plans
Beginning balance at January 1, 2012	$	—			$	1,248.40			$	870.2			$	138			$	2,256.60

Actual return on plan assets, including changes in foreign exchange rates:
Relating to assets still held at the reporting date	0.3				18.3				10.1				3.3				32

Relating to assets sold during the period	—				(0.2		)		—				—				(0.2		)

Purchases, sales, and settlements, net	2.3				(48.4		)		30.2				1.3				(14.6		)

Transfers into (out of) Level 3	1.1				—				—				—				1.1

Ending balance at December 31, 2012	$	3.7			$	1,218.10			$	910.5			$	142.6			$	2,274.90

Retiree Health Benefit Plans
Beginning balance at January 1, 2012	$	—			$	105.3			$	79.9							$	185.2

Actual return on plan assets, including changes in foreign exchange rates:
Relating to assets still held at the reporting date	—				(0.9		)		—								(0.9		)

Relating to assets sold during the period	—				—				—								—

Purchases, sales, and settlements, net	0.3				(4.5		)		2								(2.2		)

Transfers into (out of) Level 3	0.1				—				—								0.1

Ending balance at December 31, 2012	$	0.4			$	99.9			$	81.9							$	182.2

Contributions to our global defined benefit pension and post-retirement health benefit plans to satisfy minimum funding requirements as well as additional discretionary funding in the aggregate are not expected to be material during 2014.

Contingencies

Contingencies	12 Months Ended
Contingencies	Dec. 31, 2013
Loss Contingency, Information about Litigation Matters [Abstract]	'
Contingencies [Text Block]	'
	Note 16: Contingencies
	We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as specifically noted below with respect to the Alimta® patent litigation and administrative proceedings, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period.
	Alimta Patent Litigation and Administrative Proceedings
	We are engaged in various U.S. patent litigation matters involving Alimta brought pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). Teva Parenteral Medicines, Inc. (Teva); APP Pharmaceuticals, LLC (APP); Barr Laboratories, Inc. (Barr); Pliva Hrvatska D.O.O. (Pliva); Accord Healthcare Inc. (Accord); and Apotex Inc. (Apotex) each submitted Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Alimta prior to the expiration of our vitamin dosage regimen patent (expiring in 2021 plus pediatric exclusivity expiring in 2022) and alleging the patent is invalid.
	In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP, Pliva, and Barr seeking rulings that the patent is valid and infringed. Trial in this case occurred in August 2013, and we are awaiting a decision. In January 2012 and April 2012, we filed similar lawsuits in the same court against Accord and Apotex, respectively. We filed a second lawsuit against Accord in February 2013. In September 2013, we filed a similar lawsuit in the same court against Sun Pharmaceutical Industries, Ltd. and Sun Pharma Global seeking a ruling that Lilly's patent is valid and infringed. In January 2014, we filed a similar lawsuit in the same court against Glenmark Generics Inc., USA, seeking a ruling that Lilly’s patent is valid and infringed. The Accord and Apotex cases have been consolidated and stayed by the court and the parties have agreed to be bound by the outcome of the Teva/APP litigation. In June 2013, Accord filed a petition requesting review of the patent by the U.S. Patent and Trademark Office, which was denied in October 2013. This denial is final and cannot be appealed.
	Generic manufacturers have filed an opposition to the European Patent Office's decision to grant a vitamin dosage regimen patent. The Opposition Division upheld the patent and the generic manufacturers have lodged an appeal. In addition, in the UK, Actavis Group ehf and other Actavis companies have filed litigation asking for a declaratory judgment that commercialization of certain salt forms of pemetrexed (the active ingredient in Alimta) would not infringe the vitamin dosage regimen patents in the UK, Italy, France, Germany, and Spain. This case is scheduled to be heard by the trial court in April 2014. We have commenced separate infringement proceedings against certain Actavis companies in Germany. The German case is scheduled to be heard by the trial court in March 2014.
	We believe our Alimta vitamin dosage patents are valid and enforceable against these generic manufacturers and we expect to prevail in these proceedings. However, it is not possible to determine the outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenues in the relevant market.
	Byetta Product Liability Litigation
	We have been named as a defendant in approximately 275 Byetta product liability lawsuits involving approximately 700 plaintiffs. Approximately 95 of these lawsuits, covering about 510 plaintiffs, are filed in California and coordinated in a Los Angeles Superior Court. Approximately 190 of these lawsuits, involving approximately 265 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer). We are aware of approximately 460 additional claimants who have not yet filed suit. The majority of these additional claims allege damages for pancreatitis. We believe these lawsuits and claims are without merit and are prepared to defend against them vigorously.
	Prozac® Product Liability Litigation
	We have been named as a defendant in approximately 10 U.S. lawsuits primarily related to allegations that the antidepressant Prozac caused or contributed to birth defects in the children of women who ingested the drug during pregnancy. We are aware of approximately 370 additional claims related to birth defects, which have not yet been filed. We believe these lawsuits and claims are without merit and are prepared to defend against them vigorously.
	Brazil–Employee Litigation
	We have been named in a lawsuit brought by the Labor Attorney for 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly manufacturing facility in Cosmopolis, Brazil. Final arguments were submitted in September and we are awaiting a decision. We have also been named in approximately 30 lawsuits filed in the same court by individual former employees making similar claims. We believe these lawsuits are without merit and are prepared to defend against them vigorously.
	Product Liability Insurance
	Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products.

Other_Comprehensive_Income_Los

Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2013
Other Comprehensive Income (Loss), Tax [Abstract]	'
Comprehensive Income (Loss) [Text Block]	'
	Note 17: Other Comprehensive Income (Loss)
	The following table summarizes the activity related to each component of other comprehensive income (loss):


	(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)				Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
	Beginning balance at January 1, 2011	$	510.7			$	128.9		$	(3,175.8	)	$	(133.9	)	$	(2,670.1	)


	Unrealized gain (loss)					(59.4		)				32.6

	Net amount reclassed to net income					(54.7		)				(5.8		)
	Net other comprehensive income (loss)	(244.8		)		(114.1		)	(856.4		)	26.8			(1,188.5		)


	Balance at December 31, 2011	265.9				14.8			(4,032.2		)	(107.1		)	(3,858.6		)


	Unrealized gain (loss)					104.1						—

	Net amount reclassed to net income					(46.4		)				5.9

	Net other comprehensive income (loss)	160.9				57.7			(163.0		)	5.9			61.5


	Balance at December 31, 2012	426.8				72.5			(4,195.2		)	(101.2		)	(3,797.1		)


	Other comprehensive income (loss) before reclassifications	36.2				138.9			1,387.10			(86.5		)	1,475.70

	Net amount reclassified from accumulated other comprehensive loss					(6.2		)	319			5.9			318.7

	Net other comprehensive income (loss)	36.2				132.7			1,706.10			(80.6		)	1,794.40


	Ending Balance at December 31, 2013	$	463			$	205.2		$	(2,489.1	)	$	(181.8	)	$	(2,002.7	)

	The tax effect on the unrealized net gains (losses) on securities was an expense of $71.6 million in 2013, an expense of $30.8 million in 2012, and a benefit of $64.4 million in 2011. The tax effect related to our defined benefit pension and retiree health benefit plans (Note 15) was an expense of $886.1 million in 2013, an expense of $34.4 million in 2012, and a benefit of $383.8 million in 2011. The tax effect on the effective portion of cash flow hedges was a benefit of $43.2 million for the year ended December 31, 2013, and was not significant for the years ended December 31, 2012 and 2011. Income taxes were not provided for foreign currency translation.
	Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in income.


		Reclassifications Out of Accumulated Other Comprehensive Loss
	Details about Accumulated Other	Year Ended			Affected Line Item in the Consolidated Statements of Operations
	Comprehensive Loss Components	31-Dec-13
	Amortization of defined benefit items:
	Prior service benefits, net	$	(31.9	)	(1)
	Actuarial losses	515.2			(1)

	Total before tax	483.3

	Tax benefit	(164.3		)
	Net of tax	319


	Other, net of tax	(0.3		)	Other—net, (income) expense
	Total reclassifications for the period (net of tax)	$	318.7


	1	These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 15).

OtherNet_Expense_Income

Other-Net, Expense (Income)	12 Months Ended
	Dec. 31, 2013
Nonoperating Income (Expense) [Abstract]	'
Other - Net, Expense (Income) [Text Block]	'
	Note 18: Other–Net, (Income) Expense:
	Other–net, (income) expense consisted of the following:


		2013			2012			2011
	Income related to termination of the exenatide collaboration with Amylin (Note 4)	$	(495.4	)	$	(787.8	)	$	—

	Interest expense	160.1			177.8			186

	Interest income	(119.7		)	(105.0		)	(79.9		)
	Other (income) expense	(63.9		)	41			72.9

	Other–net, (income) expense	$	(518.9	)	$	(674.0	)	$	179

	For the years ended December 31, 2013 and 2012, other–net, (income) expense primarily consists of income associated with the termination of the exenatide collaboration with Amylin, including income recognized from the transfer to Amylin of exenatide commercial rights in all markets outside the U.S. in 2013 and income recognized from the early payment of the exenatide revenue-sharing obligation by Amylin in 2012. See Note 4 for additional information. For the year ended December 31, 2011, other–net, (income) expense primarily consists of the impairment on acquired IPR&D assets related to liprotamase and Amyvid (Note 8) partially offset by gains on the disposal of investment securities.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 19: Segment Information
	We operate in two business segments—human pharmaceutical products and animal health. Our business segments are distinguished by the ultimate end user of the product—humans or animals. Performance is evaluated based on profit or loss from operations before income taxes. The accounting policies of the individual segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements.
	Our human pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: endocrinology, neuroscience, oncology, cardiovascular, and other. Our endocrinology products consist primarily of Humalog®, Humulin®, Forteo®, Evista®, Humatrope®, Trajenta, and Axiron®. Neuroscience products include Cymbalta®, Zyprexa®, Strattera®, and Prozac. Cymbalta, which had U.S. sales of $3.96 billion in 2013, lost patent exclusivity in the U.S. in December 2013, resulting in the immediate entry of several generic competitors. Oncology products consist primarily of Alimta, Erbitux, and Gemzar®. Cardiovascular products consist primarily of Cialis®, Effient, and ReoPro®. The other pharmaceuticals category includes anti-infectives, primarily Vancocin® and Ceclor™, and other miscellaneous pharmaceutical products and services.
	Our animal health segment, operating through our Elanco animal health division, includes the development, manufacturing, marketing, and sales of animal health products worldwide for both food and companion animals. Animal health products include Rumensin®, Posilac®, Tylan®, Paylean®, Optaflexx® and other products for livestock and poultry, as well as Trifexis®, Comfortis®, and other products for companion animals.
	Most of our pharmaceutical products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December 31, 2013, 2012, and 2011, our three largest wholesalers each accounted for between 10 percent and 19 percent of consolidated total revenue. Further, they each accounted for between 9 percent and 18 percent of accounts receivable as of December 31, 2013 and 2012. Animal health products are sold primarily to wholesale distributors.
	We manage our assets on a total company basis, not by operating segment, as the assets of the animal health business are largely intermixed with those of the pharmaceutical products business. Therefore, our chief operating decision maker does not review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.
	We are exposed to the risk of changes in social, political, and economic conditions inherent in foreign operations, and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.


				2013				2012				2011
	Segment revenue—to unaffiliated customers:
	Human pharmaceutical products:
	Endocrinology			$	7,304.40			$	6,810.90			$	6,806.70

	Neuroscience			7,216.20				7,575.10				9,723.80

	Oncology			3,268.50				3,281.60				3,322.20

	Cardiovascular			2,923.20				2,632.50				2,486.40

	Other pharmaceuticals			249.3				266.8				268.8

	Total human pharmaceutical products			20,961.60				20,566.90				22,607.90

	Animal health			2,151.50				2,036.50				1,678.60

	Total segment revenue			$	23,113.10			$	22,603.40			$	24,286.50


	Segment profits(1):
	Human pharmaceutical products			$	5,015.00			$	4,393.40			$	5,837.90

	Animal health			556.6				508.1				301

	Total segment profits			$	5,571.60			$	4,901.50			$	6,138.90


	Reconciliation of total segment profits to consolidated income before taxes:
	Segment profits			$	5,571.60			$	4,901.50			$	6,138.90

	Other profits (losses):
	Income related to termination of the exenatide collaboration with Amylin (Note 4)			495.4				787.8				—

	Acquired in-process research and development (Notes 3 and 4)			(57.1		)		—				(388.0		)

	Asset impairment, restructuring, and other special charges (Note 5)			(120.6		)		(281.1		)		(401.4		)
	Total consolidated income before taxes			$	5,889.30			$	5,408.20			$	5,349.50


	1	Human pharmaceutical products segment profit includes total depreciation and amortization expense of $1.35 billion, $1.37 billion, and $1.30 billion for the years ended December 31, 2013, 2012, and 2011, respectively. Animal health segment profit includes total depreciation and amortization expense of $99.4 million, $91.1 million, and $78.1 million for the years ended December 31, 2013, 2012, and 2011, respectively.
	For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing, global administrative services, certain acquisition-related transaction costs, and manufacturing variances.


				2013				2012				2011
	Geographic Information
	Revenue—to unaffiliated customers(1):
	United States			$	12,889.70			$	12,313.10			$	12,977.20

	Europe			4,338.40				4,259.70				5,290.90

	Japan			2,063.80				2,246.20				2,104.10

	Other foreign countries			3,821.20				3,784.40				3,914.30

Revenue			$	23,113.10			$	22,603.40			$	24,286.50


Long-lived assets(2):
United States			$	4,649.60			$	5,064.70			$	5,485.30

Europe			2,469.70				2,281.10				2,220.20

Japan			81.1				101.5				102.9

Other foreign countries			1,540.90				1,543.20				1,564.00

Long-lived assets			$	8,741.30			$	8,990.50			$	9,372.40


1	Revenue is attributed to the countries based on the location of the customer.

2	Long-lived assets consist of property and equipment and certain sundry assets.

Selected_Quarterly_Data_Notes

Selected Quarterly Data (Notes)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information [Text Block]	'
	Note 20: Selected Quarterly Data (unaudited)


	2013	Fourth			Third			Second			First
	Revenue	$	5,808.80		$	5,772.60		$	5,929.70		$	5,602.00

	Cost of sales	1,386.50			1,198.10			1,165.20			1,158.30

	Operating expenses(1)	3,429.00			3,029.80			3,198.00			3,000.10

	Acquired IPR&D	57.1			—			—			—

	Asset impairment, restructuring, and other special charges	35.4			—			63.5			21.7

	Other—net, (income) expense	(9.1		)	31.3			(11.9		)	(529.2		)

	Income before income taxes	909.9			1,513.40			1,514.90			1,951.10

	Net income	727.5			1,203.10			1,206.20			1,548.00

	Earnings per share—basic	0.68			1.11			1.12			1.42

	Earnings per share—diluted	0.67			1.11			1.11			1.42

	Dividends paid per share	0.49			0.49			0.49			0.49

	Common stock closing prices:
	High	51.34			54.96			58.33			56.79

	Low	47.65			49.92			49.06			49.51


	2012	Fourth			Third			Second			First
	Revenue	$	5,957.30		$	5,443.30		$	5,600.70		$	5,602.00

	Cost of sales	1,248.30			1,203.60			1,146.70			1,197.90

	Operating expenses(1)	3,440.60			3,100.20			3,251.80			2,999.00

	Asset impairment, restructuring, and other special charges	204			53.3			—			23.8

	Other—net, (income) expense	52			(788.5		)	16.5			46

	Income before income taxes	1,012.40			1,874.70			1,185.70			1,335.30

	Net income	827.2			1,326.60			923.6			1,011.10

	Earnings per share—basic	0.75			1.18			0.83			0.91

	Earnings per share—diluted	0.74			1.18			0.83			0.91

	Dividends paid per share	0.49			0.49			0.49			0.49

	Common stock closing prices:
	High	53.81			47.64			42.91			41.8

	Low	45.91			41.98			39.18			38.49

	1 Includes research and development, marketing, selling, and administrative expenses
	Our common stock is listed on the New York Stock Exchange, NYSE Euronext, and SIX Swiss Exchange.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash equivalents
	We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.
Inventory, Policy [Policy Text Block]	'
	Inventories
	We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental United States. Other inventories are valued by the first-in, first-out (FIFO) method.
Investment, Policy [Policy Text Block]	'
	Investments
	Substantially all of our investments in debt and marketable equity securities are classified as available-for-sale. Investment securities with maturity dates of less than one year from the date of the balance sheet are classified as short-term. Available-for-sale securities are carried at fair value with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss). The credit portion of unrealized losses on our debt securities considered to be other-than-temporary is recognized in earnings. The remaining portion of the other-than-temporary impairment on our debt securities is then recorded, net of tax, in other comprehensive income (loss). The entire amount of other-than-temporary impairment on our equity securities is recognized in earnings. We do not evaluate cost-method investments for impairment unless there is an indicator of impairment. We review these investments for indicators of impairment on a regular basis. Realized gains and losses on sales of available-for-sale securities are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings. Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method with our share of earnings or losses reported in other–net, (income) expense. We own no investments that are considered to be trading securities.
Derivatives, Policy [Policy Text Block]	'
	Risk-management instruments
	Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and do not create additional risk because gains and losses on derivative contracts offset losses and gains on the assets, liabilities, and transactions being hedged. As derivative contracts are initiated, we designate the instruments individually as either a fair value hedge or a cash flow hedge. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.
	For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change.
	We may enter into foreign currency forward contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.
	In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.
	Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements.
	We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.
	We may enter into forward-starting interest rate swaps as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the debt agreement.
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Goodwill and other intangibles
	Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized.
	Intangible assets with finite lives are capitalized and are amortized on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years.
	The costs of in-process research and development (IPR&D) projects acquired directly in a transaction other than a business combination are capitalized if the projects have an alternative future use; otherwise, they are expensed. The fair values of IPR&D projects acquired in business combinations are capitalized as other intangible assets. Several methods may be used to determine the estimated fair value of the IPR&D acquired in a business combination. We utilize the “income method,” which applies a probability weighting that considers the risk of development and commercialization, to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each project independently. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are tested for impairment and amortized over the remaining useful life or written off, as appropriate. For transactions other than a business combination, we also capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing and amortize those amounts over the remaining estimated useful life of the underlying asset.
	Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually and when impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived IPR&D assets for impairment testing purposes, we utilize the "income method" discussed in the previous paragraph. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and equipment
	Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and 3 to 18 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.
Commitments and Contingencies, Policy [Policy Text Block]	'
	Litigation and environmental liabilities
	Litigation accruals, environmental liabilities, and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when both probable and reasonably estimable. For substantially all of our currently marketed products, we are completely self-insured for product liability losses.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue recognition
	We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. Provisions for returns, discounts, and rebates are established in the same period the related sales are recognized.
	We also generate income as a result of collaboration agreements. Revenue from co-promotion arrangements is based upon gross margins reported to us by our co-promotion partners. Initial fees we receive from the partnering of our compounds under development where we have continuing involvement are generally amortized through the expected product approval date. For out-licensing agreements that include both the sale of marketing rights to our commercialized products and a related commitment to supply the products, the initial fees received are generally recognized in net product sales over the term of the supply agreement when we have determined that the marketing rights do not have value on a standalone basis. We immediately recognize the full amount of developmental milestone payments due to us upon the achievement of the milestone event if the event is objectively determinable and the milestone is substantive in its entirety. A milestone is considered substantive if the consideration earned 1) relates solely to past performance, 2) is commensurate with the enhancement in the pharmaceutical product's value associated with the achievement of the important event in its development life cycle, and 3) is reasonable relative to all of the deliverables and payment terms within the arrangement. Milestone payments earned by us are generally recorded in other–net, (income) expense. If the payment to us is a commercialization payment that is part of a multiple-element collaborative commercialization arrangement and is a result of the initiation of the commercialization period (e.g., payments triggered by regulatory approval for marketing or launch of the product), we amortize the payment to income as we perform under the terms of the arrangement. See Note 4 for specific agreement details.
	Royalty revenue from licensees, which is based on third-party sales of licensed products and technology, is recorded as earned in accordance with the contract terms when third-party sales can be reasonably measured and collection of the funds is reasonably assured. This royalty revenue is included in collaboration and other revenue.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and development expenses and acquired IPR&D
	Research and development expenses include the following:

	•	Research and development costs, which are expensed as incurred.

	•	Milestone payment obligations incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.
	Acquired IPR&D expense includes the initial costs of IPR&D projects acquired directly in asset acquisitions, unless they have an alternative future use.
Income Tax, Policy [Policy Text Block]	'
	Income taxes
	Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the U.S. and be taxable. When foreign earnings are expected to be indefinitely reinvested outside the U.S., no accrual for U.S. income taxes is provided.
	We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.
Earnings Per Share, Policy [Policy Text Block]	'
	Earnings per share
	We calculate basic earnings per share based on the weighted-average number of common shares outstanding and incremental shares. We calculate diluted earnings per share based on the weighted-average number of common shares outstanding, including incremental shares and dilutive stock options. See Note 13 for further discussion.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-based compensation
	We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. Under our policy, all stock-based awards are approved prior to the date of grant. The compensation committee of the board of directors approves the value of the award and date of grant. Stock-based compensation that is awarded as part of our annual equity grant is made on a specific grant date scheduled in advance.

Financial_Instruments_Policies

Financial Instruments (Policies)	12 Months Ended
Financial Instruments (Policies)	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Description of Derivative Risk Management Policy	'Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-sciences products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions.B We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations.B Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 6: Inventories
	Inventories at December 31 consisted of the following:


		2013			2012
	Finished products	$	968.1		$	834.4

	Work in process	1,868.30			1,735.80

	Raw materials and supplies	259			256.1

		3,095.40			2,826.30

	Reduction to LIFO cost	(166.6		)	(182.5		)
	Inventories	$	2,928.80		$	2,643.80

	Inventories valued under the LIFO method comprised $1.02 billion and $994.3 million of total inventories at December 31, 2013 and 2012, respectively.
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 9: Property and Equipment
	At December 31, property and equipment consisted of the following:


		2013			2012
	Land	$	198.7		$	201.4

	Buildings	6,489.90			6,373.80

	Equipment	7,752.70			7,542.90

	Construction in progress	1,205.40			799.9

		15,646.70			14,918.00

	Less accumulated depreciation	(7,671.2		)	(7,157.8		)
	Property and equipment, net	$	7,975.50		$	7,760.20

	Depreciation expense for the years ended December 31, 2013, 2012, and 2011 was $774.8 million, $754.0 million, and $732.4 million, respectively. Interest costs of $24.1 million, $21.0 million, and $25.7 million were capitalized as part of property and equipment for the years ended December 31, 2013, 2012, and 2011, respectively. Total rental expense for all leases, including contingent rentals (not material), amounted to $227.2 million, $262.2 million, and $267.4 million for the years ended December 31, 2013, 2012, and 2011, respectively. Assets under capital leases included in property and equipment, net on the consolidated balance sheets, capital lease obligations entered into, and future minimum rental commitments are not material.

Collaborations_Tables

Collaborations (Tables)	12 Months Ended
	Dec. 31, 2013
Erbitux [Member]	'
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	'
	The following table summarizes our revenue recognized with respect to Erbitux:


		2013		2012		2011
	Net product sales	$	58.5	$	76.4	$	87.6

	Collaboration and other revenue	315.2		320.6		321.6

	Total revenue	$	373.7	$	397	$	409.2

Exenatide [Member]	'
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	'
	The following table summarizes the revenue and other income recognized with respect to exenatide:


		2013		2012		2011
	Net product sales	$	133.1	$	207.8	$	179.6

	Collaboration and other revenue	—		70.1		243.1

	Total revenue	$	133.1	$	277.9	$	422.7


	Income related to termination of the exenatide collaboration with Amylin(1)	$	495.4	$	787.8	$	—

	1 Presented in other-net, (income) expense

Asset_Impairments_Restructurin1

Asset Impairments, Restructuring, and Other Special Charges (Tables)	12 Months Ended
	Dec. 31, 2013
Other Nonoperating Income (Expense) [Abstract]	'
Schedule of Other Operating Cost and Expense, by Component [Table Text Block]	'
	The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below.


		2013		2012		2011
	Severance	$	90.6	$	74.5	$	251.8

	Asset impairment and other special charges	30		206.6		149.6

	Asset impairment, restructuring, and other special charges	$	120.6	$	281.1	$	401.4

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory [Line Items]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventories at December 31 consisted of the following:


		2013			2012
	Finished products	$	968.1		$	834.4

	Work in process	1,868.30			1,735.80

	Raw materials and supplies	259			256.1

		3,095.40			2,826.30

	Reduction to LIFO cost	(166.6		)	(182.5		)
	Inventories	$	2,928.80		$	2,643.80

Financial_Instruments_Tables

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]	'
	The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2013:


		Maturities by Period
		Total				Less Than				5-Jan			10-Jun			More Than
						1 Year				Years			Years			10 Years
	Fair value of debt securities	$	8,400.20			$	1,210.80			$	5,977.40		$	471.3		$	740.7

Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]	'
	The following effects of risk-management instruments were recognized in other—net, (income) expense:


		2013				2012				2011
	Fair value hedges:
	Effect from hedged fixed-rate debt	$	(308.2	)		$	51.5			$	259.6

	Effect from interest rate contracts	308.2				(51.5		)		(259.6		)

	Cash flow hedges:
	Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	9				9				9

	Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments	15.4				(35.8		)		97.4

Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
	The following tables summarize certain fair value information at December 31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:


										Fair Value Measurements Using
	Description	Carrying				Amortized				Quoted Prices in Active Markets for Identical Assets			Significant			Significant		Fair
		Amount				Cost				(Level 1)			Other			Unobservable		Value
													Observable			Inputs
													Inputs			(Level 3)
													(Level 2)
	31-Dec-13
	Cash and cash equivalents	$	3,830.20			$	3,830.20			$	3,772.60		$	57.6		$		$	3,830.20

	Short-term investments:
	U.S. government and agencies	$	276.4			$	276.6			$	276.4		$			$		$	276.4

	Corporate debt securities	931.7				929.8							931.7					931.7

	Other securities	2.7				2.7							2.7					2.7

	Marketable equity	356.3				75				356.3								356.3

	Short-term investments	$	1,567.10			$	1,284.10

	Noncurrent investments:
	U.S. government and agencies	$	1,115.60			$	1,126.10			$	1,035.60		$	80		$		$	1,115.60

	Corporate debt securities	4,940.50				4,933.70							4,940.50					4,940.50

	Mortgage-backed	636				652.4							636					636

	Asset-backed	490				494.5							490					490

	Other securities	7.3				8.3							7.3					7.3

	Marketable equity	81.2				22.8				81.2								81.2

	Equity method and other investments(1)	354.3				354.3

	Noncurrent investments	$	7,624.90			$	7,592.10


	31-Dec-12
	Cash and cash equivalents	$	4,018.80			$	4,018.80			$	3,964.40		$	54.4		$		$	4,018.80

	Short-term investments:
	U.S. government and agencies	$	150.2			$	150.2			$	150.2		$			$		$	150.2

	Corporate debt securities	1,503.50				1,501.50							1,503.50					1,503.50

	Other securities	11.8				11.8							11.8					11.8

	Short-term investments	$	1,665.50			$	1,663.50

	Noncurrent investments:
	U.S. government and agencies	$	1,362.70			$	1,360.30			$	1,122.40		$	240.3		$		$	1,362.70

	Corporate debt securities	3,351.30				3,322.90							3,351.30					3,351.30

	Mortgage-backed	668.1				677.7							668.1					668.1

	Asset-backed	519				523.5							519					519

	Other securities	3.3				3.3							3.3					3.3

Marketable equity	175.8				83				175.8								175.8

Equity method and other investments(1)	233.7				233.7

Noncurrent investments	$	6,313.90			$	6,204.40


1	Fair value not applicable
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	'


						Fair Value Measurements Using
	Description	Carrying				Quoted Prices in Active Markets for Identical Assets		Significant				Significant	Fair
		Amount				(Level 1)		Other				Unobservable	Value
								Observable				Inputs
								Inputs				(Level 3)
								(Level 2)
	Long-term debt, including current portion
	December 31, 2013	$	(5,212.9	)		$		$	(5,490.9	)		$	$	(5,490.9	)
	31-Dec-12	(5,531.3		)				(5,996.6		)			(5,996.6		)

Fair Value, by Balance Sheet Grouping [Table Text Block]	'


						Fair Value Measurements Using
	Description	Carrying				Quoted Prices in Active Markets for Identical Assets		Significant				Significant	Fair
		Amount				(Level 1)		Other				Unobservable	Value
								Observable				Inputs
								Inputs				(Level 3)
								(Level 2)
	31-Dec-13
	Risk-management instruments
	Interest rate contracts designated as hedging instruments:
	Other receivables	$	20.1			$		$	20.1			$	$	20.1

	Sundry	278.7						278.7					278.7

	Other noncurrent liabilities	(0.9		)				(0.9		)			(0.9		)
	Foreign exchange contracts not designated as hedging instruments:
	Other receivables	6.7						6.7					6.7

	Other current liabilities	(7.1		)				(7.1		)			(7.1		)
	Equity contracts designated as hedging instruments:
	Other current liabilities	(149.6		)				(149.6		)			(149.6		)

	31-Dec-12
	Risk-management instruments
	Interest rate contracts designated as hedging instruments:
	Sundry	589.4						589.4					589.4

	Foreign exchange contracts not designated as hedging instruments:
	Other receivables	11						11					11

	Other current liabilities	(17.5		)				(17.5		)			(17.5		)
Available-for-sale Securities [Table Text Block]	'
	A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:


		2013				2012
	Unrealized gross gains	$	375.6			$	140.5

	Unrealized gross losses	59.8				29

	Fair value of securities in an unrealized gain position	4,982.70				5,246.00

	Fair value of securities in an unrealized loss position	3,664.70				2,102.00

Gain (Loss) on Investments [Table Text Block]	'
	Activity related to our investment portfolio, substantially all of which related to available-for-sale securities, was as follows:


		2013				2012				2011
	Proceeds from sales	$	13,753.50			$	6,529.80			$	2,268.30

	Realized gross gains on sales	49.5				82.3				140

	Realized gross losses on sales	15.4				10.9				9.9

Goodwill_and_Other_Intangibles1

Goodwill and Other Intangibles (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	'
	Goodwill and other indefinite-lived intangible assets at December 31 were as follows:


		2013		2012
	Goodwill (by segment):
	Human pharmaceutical products	$	1,354.70	$	1,364.20

	Animal health	162.1		137.1

	Total goodwill	1,516.80		1,501.30

	In-process research and development	33.6		65

	Total indefinite-lived intangible assets	$	1,550.40	$	1,566.30

Schedule of Intangible Assets and Goodwill [Table Text Block]	'
	The components of finite-lived intangible assets at December 31 were as follows:


		2013							2012
	Description	Carrying		Accumulated			Carrying		Carrying		Accumulated			Carrying
		Amount—		Amortization			Amount—		Amount—		Amortization			Amount—
		Gross					Net		Gross					Net
	Marketed products	$	5,136.10	$	(2,447.2	)	$	2,688.90	$	5,107.90	$	(1,987.0	)	$	3,120.90

	Other	164.8		(73.0		)	91.8		129.5		(64.0		)	65.5

	Total finite-lived intangible assets	$	5,300.90	$	(2,520.2	)	$	2,780.70	$	5,237.40	$	(2,051.0	)	$	3,186.40

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment [Table Text Block]	'
	At December 31, property and equipment consisted of the following:


		2013			2012
	Land	$	198.7		$	201.4

	Buildings	6,489.90			6,373.80

	Equipment	7,752.70			7,542.90

	Construction in progress	1,205.40			799.9

		15,646.70			14,918.00

	Less accumulated depreciation	(7,671.2		)	(7,157.8		)
	Property and equipment, net	$	7,975.50		$	7,760.20

Borrowings_Tables

Borrowings (Tables)	12 Months Ended
	Dec. 31, 2013
Long-term Debt, Current and Noncurrent [Abstract]	'
Schedule of Debt [Table Text Block]	'
	Long-term debt at December 31 consisted of the following:


		2013			2012
	4.20 to 7.13 percent notes (due 2014-2037)	$	4,887.30		$	4,887.30

	Other, including capitalized leases	27.1			37.4

	Fair value adjustment	298.5			606.6

		5,212.90			5,531.30

	Less current portion	(1,012.6		)	(11.9		)
	Long-term debt	$	4,200.30		$	5,519.40

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Share-based Compensation Awards, Fair Value Assumptions Used [Table Text Block]	'
	The weighted-average fair values of the SVA units granted during the years ended December 31, 2013, 2012, and 2011 were $45.17, $30.35, and $28.33, respectively, determined using the following assumptions:


	(Percents)	2013		2012		2011
	Expected dividend yield	3.5	%	4.5	%	4.9	%
	Risk-free interest rate	.08-.43		.10-.36		.20-1.36

	Range of volatilities	18.95-22.37		22.40-25.64		27.61-29.10

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	Stock option activity during the year ended December 31, 2013 is summarized below:


		Shares of		Weighted-Average			Weighted-Average	Aggregate
		Common Stock		Exercise			Remaining	Intrinsic
		Attributable to		Price of Options			Contractual Term	Value
		Options					(in years)
		(in thousands)
	Outstanding at January 1, 2013	27,232		$	63.89

	Exercised	(208	)	54.27

	Forfeited or expired	(10,884	)	59.95

	Outstanding at December 31, 2013	16,140		66.66			0.7	$	—

	Exercisable at December 31, 2013	16,140		66.66			0.7	—

Shareholder Value Awards [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Schedule of Share-based Compensation, Activity [Table Text Block]	'
	A summary of the SVA activity is presented below:


	Units Attributable to SVAs (in thousands)	2013		2012		2011
	Outstanding at January 1	7,539		7,036		6,381

	Granted	1,795		2,439		2,561

	Issued	(2,397	)	(973	)	(428	)
	Forfeited or expired	(301	)	(963	)	(1,478	)
	Outstanding at December 31	6,636		7,539		7,036

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	Following is a reconciliation of the denominators used in computing earnings per share:


	(Shares in thousands)	2013		2012		2011
	Income available to common shareholders	$	4,684.80	$	4,088.60	$	4,347.70

	Basic earnings per share:

	Weighted-average number of common shares outstanding, including incremental shares	1,080,874		1,113,178		1,113,923

	Basic earnings per share	$	4.33	$	3.67	$	3.9

	Diluted earnings per share:

	Weighted-average number of common shares outstanding, including incremental shares and stock options	1,084,766		1,117,294		1,113,967

	Diluted earnings per share	$	4.32	$	3.66	$	3.9

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	Following is the composition of income tax expense:


		2013			2012			2011
	Current:
	Federal	$	259.1		$	596.8		$	671.4

	Foreign	553.2			540.6			759.5

	State	126.3			56.2			(22.9		)

	Total current tax expense	938.6			1,193.60			1,408.00

	Deferred:
	Federal	297			87			(398.5		)

	Foreign	(28.2		)	29.9			(34.7		)

	State	(2.9		)	9.1			27

	Total deferred tax expense (benefit)	265.9			126			(406.2		)

	Income taxes	$	1,204.50		$	1,319.60		$	1,001.80

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	Significant components of our deferred tax assets and liabilities as of December 31 are as follows:


		2013			2012
	Deferred tax assets:
	Compensation and benefits	$	639.8		$	1,081.80

	Tax credit carryforwards and carrybacks	494.6			703.2

	Purchases of intangible assets	418.8			366.8

	Product return reserves	313.7			153.8

	Tax loss carryforwards and carrybacks	311.7			370.1

	Debt	110			232.8

	Contingencies	106			113.2

	Intercompany profit in inventories	104.5			159.6

	Sale of intangibles	76.5			278.6

	Other	518.5			361.5

	Total gross deferred tax assets	3,094.10			3,821.40

	Valuation allowances	(647.1		)	(675.8		)
	Total deferred tax assets	2,447.00			3,145.60

	Deferred tax liabilities:
	Unremitted earnings	(898.3		)	(920.4		)
	Inventories	(685.6		)	(573.4		)
	Intangibles	(598.9		)	(708.8		)
	Prepaid employee benefits	(446.2		)	—

	Property and equipment	(379.1		)	(407.1		)
	Financial instruments	(109.6		)	(257.0		)
	Total deferred tax liabilities	(3,117.7		)	(2,866.7		)
	Deferred tax assets (liabilities) - net	$	(670.7	)	$	278.9

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:


		2013			2012			2011
	Income tax at the U.S. federal statutory tax rate	$	2,061.30		$	1,892.90		$	1,872.30

	Add (deduct):
	International operations, including Puerto Rico	(778.3		)	(593.8		)	(796.7		)
	General business credits	(175.6		)	(11.2		)	(80.8		)
	IRS audit conclusion	(7.9		)	—			(85.3		)

	Other	105			31.7			92.3

	Income taxes	$	1,204.50		$	1,319.60		$	1,001.80

Summary of Income Tax Contingencies [Table Text Block]	'
	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:


		2013			2012			2011
	Beginning balance at January 1	$	1,534.30		$	1,369.30		$	1,714.30

	Additions based on tax positions related to the current year	142.5			144.8			89.4

	Additions for tax positions of prior years	251.5			70.1			390

	Reductions for tax positions of prior years	(358.2		)	(38.5		)	(492.3		)
	Settlements	(404.9		)	(9.2		)	(326.3		)
	Lapses of statutes of limitation	(24.9		)	(4.6		)	(2.6		)
	Changes related to the impact of foreign currency translation	(3.9		)	2.4			(3.2		)

	Ending balance at December 31	$	1,136.40		$	1,534.30		$	1,369.30

Retirement_Benefits_Tables

Retirement Benefits (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block]	'
	We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows:


		Defined Benefit								Retiree Health
		Pension Plans								Benefit Plans
		2013				2012				2013				2012
	Change in benefit obligation:
	Benefit obligation at beginning of year	$	10,423.80			$	9,191.20			$	2,337.70			$	2,308.60

	Service cost	287.1				253.1				49.9				63.3

	Interest cost	437.2				455.1				98.1				114.9

	Actuarial (gain) loss	(792.2		)		834				(642.5		)		(57.0		)

	Benefits paid	(402.3		)		(404.2		)		(79.6		)		(67.2		)
	Plan amendments	(0.1		)		(0.6		)		(4.1		)		(28.4		)
	Foreign currency exchange rate changes and other adjustments	22.9				95.2				(2.3		)		3.5

	Benefit obligation at end of year	9,976.40				10,423.80				1,757.20				2,337.70

Schedule of Changes in Fair Value of Plan Assets [Table Text Block]	'


	Change in plan assets:
	Fair value of plan assets at beginning of year	8,286.60			7,186.30			1,518.00			1,339.00

	Actual return on plan assets	1,144.60			922.7			365.7			183.4

	Employer contribution	428.9			469.7			75.5			62.8

	Benefits paid	(402.3	)		(404.2	)		(79.6	)		(67.2	)
	Foreign currency exchange rate changes and other adjustments	23.9			112.1			—			—

	Fair value of plan assets at end of year	9,481.70			8,286.60			1,879.60			1,518.00

Schedule of Net Funded Status [Table Text Block]	'


	Funded status	(494.7		)		(2,137.2		)		122.4				(819.7		)

	Unrecognized net actuarial loss	3,546.30				5,187.50				178.1				1,156.70

	Unrecognized prior service (benefit) cost	50.7				54.9				(171.5		)		(203.4		)

	Net amount recognized	$	3,102.30			$	3,105.20			$	129			$	133.6

Schedule of Amounts Recognized in Balance Sheet [Table Text Block]	'


	Amounts recognized in the consolidated balance sheet consisted of:
	Sundry	$	881.2			$	125.5			$	366.4			$	—

	Other current liabilities	(62.8		)		(61.2		)		(7.7		)		(8.9		)
	Accrued retirement benefits	(1,313.1		)		(2,201.6		)		(236.3		)		(810.8		)
	Accumulated other comprehensive loss before income taxes	3,597.00				5,242.50				6.6				953.3

	Net amount recognized	$	3,102.30			$	3,105.20			$	129			$	133.6

Schedule of Amounts in Accumulated Other Comprehensive Income (Loss) to be Recognized over Next Fiscal Year [Table Text Block]	'
	During 2014, we expect the following components of accumulated other comprehensive loss to be recognized as components of net periodic benefit cost:


		Defined Benefit				Retiree Health
		Pension Plans				Benefit Plans
	Unrecognized net actuarial loss	$	277.2			$	20

	Unrecognized prior service cost	3.6				(31.2		)

	Total	$	280.8			$	(11.2	)

Schedule of Assumptions Used [Table Text Block]	'
	The following represents our weighted-average assumptions as of December 31:


		Defined Benefit						Retiree Health
		Pension Plans						Benefit Plans
	(Percents)	2013		2012		2011		2013		2012		2011
	Discount rate for benefit obligation	4.9		4.3		5		5		4.3		5.1
	Discount rate for net benefit costs	4.3		5		5.6		4.3		5.1		5.8
	Rate of compensation increase for benefit obligation	3.4		3.4		3.7
	Rate of compensation increase for net benefit costs	3.4		3.7		3.7
	Expected return on plan assets for net benefit costs	8.4		8.4		8.5		8.8		8.8		8.8
Schedule of Expected Benefit Payments [Table Text Block]	'
	The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:


		2014				2015				2016				2017				2018			2019-2023
	Defined benefit pension plans	$	430.9			$	440.1			$	453			$	469			$	486		$	2,726.00


	Retiree health benefit plans-gross	$	94			$	98			$	102.3			$	106.4			$	111		$	612.3

	Medicare rebates	(6.8		)		(7.6		)		(8.2		)		(9.0		)		(9.8		)	(60.5		)
	Retiree health benefit plans-net	$	87.2			$	90.4			$	94.1			$	97.4			$	101.2		$	551.8

Schedule of Net Benefit Costs [Table Text Block]	'
	Net pension and retiree health benefit expense included the following components:


		Defined Benefit												Retiree Health
		Pension Plans												Benefit Plans
		2013				2012				2011				2013				2012			2011
	Components of net periodic benefit cost:
	Service cost	$	287.1			$	253.1			$	236.3			$	49.9			$	63.3		$	72.4

	Interest cost	437.2				455.1				447.9				98.1				114.9			118

	Expected return on plan assets	(701.9		)		(684.8		)		(685.9		)		(130.7		)		(127.2		)	(129.4		)
	Amortization of prior service (benefit) cost	3.7				4.2				8.6				(35.6		)		(39.8		)	(42.9		)

	Recognized actuarial loss	414.7				285.7				200.4				100.5				98.4			88.7

	Net periodic benefit cost	$	440.8			$	313.3			$	207.3			$	82.2			$	109.6		$	106.8

Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]	'
	The following represents the amounts recognized in other comprehensive income (loss) for the year ended December 31, 2013:


		Defined Benefit				Retiree Health
		Pension Plans				Benefit Plans
	Actuarial gain arising during period	$	1,234.70			$	877.6

	Plan amendments during period	0.1				4.1

	Amortization of prior service (benefit) cost included in net income	3.7				(35.6		)

	Amortization of net actuarial loss included in net income	414.7				100.5

	Foreign currency exchange rate changes	(7.7		)		0.1

	Total other comprehensive income during period	$	1,645.50			$	946.7



		Reclassifications Out of Accumulated Other Comprehensive Loss
	Details about Accumulated Other	Year Ended			Affected Line Item in the Consolidated Statements of Operations
	Comprehensive Loss Components	31-Dec-13
	Amortization of defined benefit items:
	Prior service benefits, net	$	(31.9	)	(1)
	Actuarial losses	515.2			(1)

	Total before tax	483.3

	Tax benefit	(164.3		)
	Net of tax	319


	Other, net of tax	(0.3		)	Other—net, (income) expense
	Total reclassifications for the period (net of tax)	$	318.7

Schedule of Allocation of Plan Assets [Table Text Block]	'
	The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2012 by asset category are as follows:


						Fair Value Measurements Using
	Asset Class	Total				Quoted Prices in Active Markets for Identical Assets				Significant Observable Inputs				Significant Unobservable Inputs
						(Level 1)				(Level 2)				(Level 3)
	Defined Benefit Pension Plans
	Public equity securities:
	U.S.	$	457.7			$	307.9			$	149.8			$

	International	1,905.30				673.3				1,232.00

	Fixed income:
	Developed markets	1,075.40				156.4				915.3				3.7

	Emerging markets	402.3								402.3

	Private alternative investments:
	Hedge funds	2,555.50								1,337.40				1,218.10

	Equity-like funds	991.2				17.4				63.3				910.5

	Real estate	504.3				353.5				8.2				142.6

	Other	394.9				140.1				254.8

	Total	$	8,286.60			$	1,648.60			$	4,363.10			$	2,274.90

	Retiree Health Benefit Plans
	Public equity securities:
	U.S.	$	45.4			$	30.4			$	15			$

	International	127.7				33.9				93.8

	Fixed income:
	Developed markets	59.4								59				0.4

	Emerging markets	40.3								40.3

	Private alternative investments:
	Hedge funds	234								134.1				99.9

	Equity-like funds	81.9												81.9

	Cash value of trust owned insurance contract	869.1								869.1

	Real estate	35.4				35.4

	Other	24.8				6.2				18.6

	Total	$	1,518.00			$	105.9			$	1,229.90			$	182.2

	The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2013 by asset category are as follows:


						Fair Value Measurements Using
	Asset Class	Total				Quoted Prices in Active Markets for				Significant				Significant
						Identical Assets				Observable Inputs				Unobservable Inputs
						(Level 1)				(Level 2)				(Level 3)
	Defined Benefit Pension Plans
	Public equity securities:
	U.S.	$	400.3			$	189.2			$	211.1			$

International	2,483.80				1,045.80				1,438.00

Fixed income:
Developed markets	1,036.10				170.2				850				15.9

Emerging markets	382.6								382.6

Private alternative investments:
Hedge funds	2,902.30								1,461.90				1,440.40

Equity-like funds	1,069.90								76.4				993.5

Real estate	521.4				368								153.4

Other	685.3				245.2				440.1

Total	$	9,481.70			$	2,018.40			$	4,860.10			$	2,603.20

Retiree Health Benefit Plans
Public equity securities:
U.S.	$	39.4			$	18.3			$	21.1			$

International	167.2				61.6				105.6

Fixed income:
Developed markets	54.7								53.1				1.6

Emerging markets	38.2								38.2

Private alternative investments:
Hedge funds	266.4								145.8				120.6

Equity-like funds	88.9												88.9

Cash value of trust owned insurance contract	1,136.80								1,136.80

Real estate	36.7				36.7

Other	51.3				18				33.3

Total	$	1,879.60			$	134.6			$	1,533.90			$	211.1

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The activity in the Level 3 investments during the year ended December 31, 2012 was as follows:


		Fixed Income: Developed Markets				Hedge				Equity-like				Real				Total
						Funds				Funds				Estate
	Defined Benefit Pension Plans
	Beginning balance at January 1, 2012	$	—			$	1,248.40			$	870.2			$	138			$	2,256.60

	Actual return on plan assets, including changes in foreign exchange rates:
	Relating to assets still held at the reporting date	0.3				18.3				10.1				3.3				32

	Relating to assets sold during the period	—				(0.2		)		—				—				(0.2		)

	Purchases, sales, and settlements, net	2.3				(48.4		)		30.2				1.3				(14.6		)

	Transfers into (out of) Level 3	1.1				—				—				—				1.1

	Ending balance at December 31, 2012	$	3.7			$	1,218.10			$	910.5			$	142.6			$	2,274.90

	Retiree Health Benefit Plans
	Beginning balance at January 1, 2012	$	—			$	105.3			$	79.9							$	185.2

	Actual return on plan assets, including changes in foreign exchange rates:
	Relating to assets still held at the reporting date	—				(0.9		)		—								(0.9		)

	Relating to assets sold during the period	—				—				—								—

	Purchases, sales, and settlements, net	0.3				(4.5		)		2								(2.2		)

	Transfers into (out of) Level 3	0.1				—				—								0.1

	Ending balance at December 31, 2012	$	0.4			$	99.9			$	81.9							$	182.2

	The activity in the Level 3 investments during the year ended December 31, 2013 was as follows:


		Fixed Income: Developed Markets				Hedge				Equity-like				Real				Total
						Funds				Funds				Estate
	Defined Benefit Pension Plans
	Beginning balance at January 1, 2013	$	3.7			$	1,218.10			$	910.5			$	142.6			$	2,274.90

	Actual return on plan assets, including changes in foreign exchange rates:
	Relating to assets still held at the reporting date	(3.0		)		123.4				155.7				8.5				284.6

	Relating to assets sold during the period	—				—				—				—				—

	Purchases, sales, and settlements, net	3.7				98.9				(72.7		)		2.3				32.2

	Transfers into (out of) Level 3	11.5				—				—				—				11.5

	Ending balance at December 31, 2013	$	15.9			$	1,440.40			$	993.5			$	153.4			$	2,603.20

	Retiree Health Benefit Plans
	Beginning balance at January 1, 2013	$	0.4			$	99.9			$	81.9							$	182.2

	Actual return on plan assets, including changes in foreign exchange rates:
	Relating to assets still held at the reporting date	(0.3		)		10.3				13.9								23.9

	Relating to assets sold during the period	—				—				—								—

	Purchases, sales, and settlements, net	0.4				10.4				(6.9		)						3.9

	Transfers into (out of) Level 3	1.1				—				—								1.1

Ending balance at December 31, 2013	$	1.6			$	120.6			$	88.9							$	211.1

Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]	'
	Amounts relating to defined benefit plans with projected benefit obligations in excess of plan assets were as follows at December 31:


		2013				2012
	Projected benefit obligation	$	1,773.60			$	9,151.20

	Fair value of plan assets	395.4				6,888.60

Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]	'
	Amounts relating to defined benefit plans with accumulated benefit obligations in excess of plan assets were as follows at December 31:


		2013				2012
	Accumulated benefit obligation	$	1,384.60			$	8,021.00

	Fair value of plan assets	181.8				6,580.60

Other_Comprehensive_Income_Los1

Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2013
Other Comprehensive Income (Loss), Tax [Abstract]	'
Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]	'
	The following represents the amounts recognized in other comprehensive income (loss) for the year ended December 31, 2013:


		Defined Benefit				Retiree Health
		Pension Plans				Benefit Plans
	Actuarial gain arising during period	$	1,234.70			$	877.6

	Plan amendments during period	0.1				4.1

	Amortization of prior service (benefit) cost included in net income	3.7				(35.6		)

	Amortization of net actuarial loss included in net income	414.7				100.5

	Foreign currency exchange rate changes	(7.7		)		0.1

	Total other comprehensive income during period	$	1,645.50			$	946.7



		Reclassifications Out of Accumulated Other Comprehensive Loss
	Details about Accumulated Other	Year Ended			Affected Line Item in the Consolidated Statements of Operations
	Comprehensive Loss Components	31-Dec-13
	Amortization of defined benefit items:
	Prior service benefits, net	$	(31.9	)	(1)
	Actuarial losses	515.2			(1)

	Total before tax	483.3

	Tax benefit	(164.3		)
	Net of tax	319


	Other, net of tax	(0.3		)	Other—net, (income) expense
	Total reclassifications for the period (net of tax)	$	318.7

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
	The following table summarizes the activity related to each component of other comprehensive income (loss):


	(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)				Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
	Beginning balance at January 1, 2011	$	510.7			$	128.9		$	(3,175.8	)	$	(133.9	)	$	(2,670.1	)


	Unrealized gain (loss)					(59.4		)				32.6

	Net amount reclassed to net income					(54.7		)				(5.8		)
	Net other comprehensive income (loss)	(244.8		)		(114.1		)	(856.4		)	26.8			(1,188.5		)


	Balance at December 31, 2011	265.9				14.8			(4,032.2		)	(107.1		)	(3,858.6		)


	Unrealized gain (loss)					104.1						—

	Net amount reclassed to net income					(46.4		)				5.9

	Net other comprehensive income (loss)	160.9				57.7			(163.0		)	5.9			61.5


	Balance at December 31, 2012	426.8				72.5			(4,195.2		)	(101.2		)	(3,797.1		)


	Other comprehensive income (loss) before reclassifications	36.2				138.9			1,387.10			(86.5		)	1,475.70

	Net amount reclassified from accumulated other comprehensive loss					(6.2		)	319			5.9			318.7

	Net other comprehensive income (loss)	36.2				132.7			1,706.10			(80.6		)	1,794.40


	Ending Balance at December 31, 2013	$	463			$	205.2		$	(2,489.1	)	$	(181.8	)	$	(2,002.7	)

Other_Net_Expense_Income_Table

Other - Net, Expense (Income) (Tables)	12 Months Ended
	Dec. 31, 2013
Nonoperating Income (Expense) [Abstract]	'
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	'
	Other–net, (income) expense consisted of the following:


		2013			2012			2011
	Income related to termination of the exenatide collaboration with Amylin (Note 4)	$	(495.4	)	$	(787.8	)	$	—

	Interest expense	160.1			177.8			186

	Interest income	(119.7		)	(105.0		)	(79.9		)
	Other (income) expense	(63.9		)	41			72.9

	Other–net, (income) expense	$	(518.9	)	$	(674.0	)	$	179

Segment_Information_Segment_In

Segment Information Segment Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	'


		2013			2012			2011
	Segment revenue—to unaffiliated customers:
	Human pharmaceutical products:
	Endocrinology	$	7,304.40		$	6,810.90		$	6,806.70

	Neuroscience	7,216.20			7,575.10			9,723.80

	Oncology	3,268.50			3,281.60			3,322.20

	Cardiovascular	2,923.20			2,632.50			2,486.40

	Other pharmaceuticals	249.3			266.8			268.8

	Total human pharmaceutical products	20,961.60			20,566.90			22,607.90

	Animal health	2,151.50			2,036.50			1,678.60

	Total segment revenue	$	23,113.10		$	22,603.40		$	24,286.50


	Segment profits(1):
	Human pharmaceutical products	$	5,015.00		$	4,393.40		$	5,837.90

	Animal health	556.6			508.1			301

	Total segment profits	$	5,571.60		$	4,901.50		$	6,138.90


	Reconciliation of total segment profits to consolidated income before taxes:
	Segment profits	$	5,571.60		$	4,901.50		$	6,138.90

	Other profits (losses):
	Income related to termination of the exenatide collaboration with Amylin (Note 4)	495.4			787.8			—

	Acquired in-process research and development (Notes 3 and 4)	(57.1		)	—			(388.0		)

	Asset impairment, restructuring, and other special charges (Note 5)	(120.6		)	(281.1		)	(401.4		)
	Total consolidated income before taxes	$	5,889.30		$	5,408.20		$	5,349.50

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	'


		2013			2012			2011
	Geographic Information
	Revenue—to unaffiliated customers(1):
	United States	$	12,889.70		$	12,313.10		$	12,977.20

	Europe	4,338.40			4,259.70			5,290.90

	Japan	2,063.80			2,246.20			2,104.10

	Other foreign countries	3,821.20			3,784.40			3,914.30

	Revenue	$	23,113.10		$	22,603.40		$	24,286.50


	Long-lived assets(2):
	United States	$	4,649.60		$	5,064.70		$	5,485.30

	Europe	2,469.70			2,281.10			2,220.20

	Japan	81.1			101.5			102.9

	Other foreign countries	1,540.90			1,543.20			1,564.00

	Long-lived assets	$	8,741.30		$	8,990.50		$	9,372.40

Selected_Quarterly_Data_Tables

Selected Quarterly Data (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information [Table Text Block]	'


	2013	Fourth			Third			Second			First
	Revenue	$	5,808.80		$	5,772.60		$	5,929.70		$	5,602.00

	Cost of sales	1,386.50			1,198.10			1,165.20			1,158.30

	Operating expenses(1)	3,429.00			3,029.80			3,198.00			3,000.10

	Acquired IPR&D	57.1			—			—			—

	Asset impairment, restructuring, and other special charges	35.4			—			63.5			21.7

	Other—net, (income) expense	(9.1		)	31.3			(11.9		)	(529.2		)

	Income before income taxes	909.9			1,513.40			1,514.90			1,951.10

	Net income	727.5			1,203.10			1,206.20			1,548.00

	Earnings per share—basic	0.68			1.11			1.12			1.42

	Earnings per share—diluted	0.67			1.11			1.11			1.42

	Dividends paid per share	0.49			0.49			0.49			0.49

	Common stock closing prices:
	High	51.34			54.96			58.33			56.79

	Low	47.65			49.92			49.06			49.51


	2012	Fourth			Third			Second			First
	Revenue	$	5,957.30		$	5,443.30		$	5,600.70		$	5,602.00

	Cost of sales	1,248.30			1,203.60			1,146.70			1,197.90

	Operating expenses(1)	3,440.60			3,100.20			3,251.80			2,999.00

	Asset impairment, restructuring, and other special charges	204			53.3			—			23.8

	Other—net, (income) expense	52			(788.5		)	16.5			46

	Income before income taxes	1,012.40			1,874.70			1,185.70			1,335.30

	Net income	827.2			1,326.60			923.6			1,011.10

	Earnings per share—basic	0.75			1.18			0.83			0.91

	Earnings per share—diluted	0.74			1.18			0.83			0.91

	Dividends paid per share	0.49			0.49			0.49			0.49

	Common stock closing prices:
	High	53.81			47.64			42.91			41.8

	Low	45.91			41.98			39.18			38.49

	1 Includes research and development, marketing, selling, and administrative expenses

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Average Remaining Maturity of Foreign Currency Derivatives	'	'	'	'	'	'	'	'	'12 months	'	'
Finite-Lived Intangible Assets, Useful Life, Minimum	'	'	'	'	'	'	'	'	'8 years	'	'
Depreciation	'	'	'	'	'	'	'	'	$774.80	$754	$732.40
Interest Costs, Capitalized During Period	'	'	'	'	'	'	'	'	24.1	21	25.7
Operating Leases, Rent Expense	'	'	'	'	'	'	'	'	227.2	262.2	267.4
Collaboration and other revenue	'	'	'	'	'	'	'	'	707.5	633	681.7
Revenue	$5,808.80	$5,772.60	$5,929.70	$5,602	$5,957.30	$5,443.30	$5,600.70	$5,602	$23,113.10	$22,603.40	$24,286.50
Minimum [Member]	'	'	'	'	'	'	'	'	'	'	'
Finite-Lived Intangible Assets, Useful Life, Minimum	'	'	'	'	'	'	'	'	'3 years	'	'
Minimum [Member] \| Building [Member]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Useful Life, Minimum	'	'	'	'	'	'	'	'	'12 years	'	'
Minimum [Member] \| Equipment [Member]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Useful Life, Minimum	'	'	'	'	'	'	'	'	'3 years	'	'
Maximum [Member]	'	'	'	'	'	'	'	'	'	'	'
Finite-Lived Intangible Assets, Useful Life, Minimum	'	'	'	'	'	'	'	'	'20 years	'	'
Maximum [Member] \| Building [Member]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Useful Life, Minimum	'	'	'	'	'	'	'	'	'50 years	'	'
Maximum [Member] \| Equipment [Member]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment, Useful Life, Minimum	'	'	'	'	'	'	'	'	'18 years	'	'

Acquisitions_Details

Acquisitions (Details) (USD $)	3 Months Ended				12 Months Ended			0 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 07, 2011	Feb. 17, 2012
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Janssen Pharmaceutica NV (J&J) [Member]	ChemGen [Member]
Business Combination, Consideration Transferred	'	'	'	'	'	'	'	$307.80	$206.90
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	'	'	'	'	'	'	'	234.4	151.5
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	'	'	'	'	'	'	'	29.6	'
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	'	'	'	'	'	'	'	43.8	55.4
Business Acquisition, Products or Other Assets Acquired	'	'	'	'	'	'	'	50	'
Acquired in-process research and development	$57.10	$0	$0	$0	$57.10	$0	$388	'	'

Collaborations_Details

Collaborations (Details)

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

11 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

11 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Aug. 31, 2012

Nov. 30, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Nov. 30, 2011

Jun. 30, 2011

Nov. 30, 2011

Aug. 31, 2012

Nov. 30, 2011

Dec. 31, 2008

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Mar. 31, 2011

Dec. 31, 2009

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2009

Nov. 30, 2011

Dec. 31, 2008

USD ($)

Erbitux [Member]

Effient [Member]

Amylin [Member]

Exenatide [Member]

Boerhringer Ingelheim (BI) [Member]

Tanezumab [Member]

United States [Member]

Secured Note [Member]

Loan Commitment [Member]

Sales New [Member]

Revenue Share [Member]

Milestone Payments [Member]

Milestone Payments, Sales-based [Member]

Milestone Payments, Development and Regulatory [Member]

Profit And Development And Marketing Share [Member]

Royalty [Member]

Research And Development Exp [Member]

Research And Development And Marketing And Selling Expense [Member]

Gross Margin Share [Member]

Royalty Payments Received [Member]

USD ($)

Amylin [Member]

Exenatide Once Weekly [Member]

Amylin [Member]

Outside the United States [Member]

Amylin [Member]

United States [Member]

Outside the United States [Member]

Amylin [Member]

Solanezumab [Member]

BI compounds [Member]

LLY compounds [Member]

LLY optional compound [Member]

Baricitinib [Member]

Tanezumab [Member]

LLY compounds [Member]

Baricitinib [Member]

Tanezumab [Member]

Effient [Member]

Baricitinib [Member]

United States [Member]

Solanezumab [Member]

USD ($)

Exenatide [Member]

USD ($)

Amylin [Member]

USD ($)

EUR (€)

USD ($)

Exenatide [Member]

Sales Revenue, Goods, Net

$58,500,000

$76,400,000

$87,600,000

$508,700,000

$457,200,000

$302,500,000

$133,100,000

$207,800,000

$179,600,000

Collaboration and other revenue

707,500,000

633,000,000

681,700,000

315,200,000

320,600,000

321,600,000

70,100,000

243,100,000

249,200,000

88,600,000

15,100,000

Total Revenue

5,808,800,000

5,772,600,000

5,929,700,000

5,602,000,000

5,957,300,000

5,443,300,000

5,600,700,000

5,602,000,000

23,113,100,000

22,603,400,000

24,286,500,000

373,700,000

397,000,000

409,200,000

133,100,000

277,900,000

422,700,000

12,889,700,000

12,313,100,000

12,977,200,000

Other Nonoperating Income (Expense)

63,900,000

-41,000,000

-72,900,000

787,800,000

495,400,000

Research and Development Expense

5,531,300,000

5,278,100,000

5,020,800,000

Proceeds from prepayment of revenue-sharing obligation

1,212,100,000

1,210,000,000

Collaborative Arrangement, Income Statement Classification and Amounts

203,700,000

188,500,000

125,400,000

Collaborative Arrangement, Rights and Obligations

-250,000,000

-1,260,000,000

-150,000,000

-70,000,000

-225,000,000

-478,700,000

250,000,000

525,000,000

-150,000,000

50,000,000

-50,000,000

-415,000,000

Collaborative Arrangement, Rights and Obligations, Terms

97,200,000

1,230,000,000

350,000,000

Collaborative Arrangement, Rights and Obligations Percent

15.00%

100.00%

65.00%

35.00%

50.00%

20.00%

30.00%

50.00%

Proceeds from Sales of Business, Affiliate and Productive Assets

1,200,000,000

Debt Instrument, Interest Rate, Stated Percentage

9.50%

Collaborative Arrangement, Rights and Obligations, Term of Arrangement

'10 years

Acquired in-process research and development

57,100,000

388,000,000

200,000,000

Payments to Fund Long-term Loans to Related Parties

$165,000,000

Asset_Impairments_Restructurin2

Asset Impairments, Restructuring, and Other Special Charges (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Unusual or Infrequent Item [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Total Asset impairment, restructuring, and other special charges	$35.40	$0	$63.50	$21.70	$204	$53.30	$0	$23.80	$120.60	$281.10	$401.40
Asset Impairment Charges	'	'	'	'	'	'	'	'	30	206.6	149.6
Severance Costs	'	'	'	'	'	'	'	'	90.6	74.5	251.8
Xigris [Member]	'	'	'	'	'	'	'	'	'	'	'
Unusual or Infrequent Item [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Asset Impairment Charges	'	'	'	'	'	'	'	'	'	20	85
Leases [Member]	'	'	'	'	'	'	'	'	'	'	'
Unusual or Infrequent Item [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Asset Impairment Charges	'	'	'	'	'	'	'	'	'	'	56.1
Device Delivery Platform [Member]	'	'	'	'	'	'	'	'	'	'	'
Unusual or Infrequent Item [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Asset Impairment Charges	'	'	'	'	'	'	'	'	'	64	'
Liprotamase [Member]	'	'	'	'	'	'	'	'	'	'	'
Unusual or Infrequent Item [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Asset Impairment Charges	'	'	'	'	'	'	'	'	'	$122.60	'

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Inventory [Line Items]	'	'
LIFO Inventory Amount	$1,020	$994.30
Finished products	968.1	834.4
Work in process	1,868.30	1,735.80
Raw materials and supplies	259	256.1
Inventory, Gross, Total	3,095.40	2,826.30
Reduction to LIFO cost	-166.6	-182.5
Inventories	$2,928.80	$2,643.80

Financial_Instruments_Details

Financial Instruments (Details)

12 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

USD ($)

Hedged Fixed-Rate Debt [Member]

Equity Contract [Member]

Interest Rate Contract [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Corporate Debt Securities [Member]

US Government Agencies Debt Securities [Member]

Other Debt Obligations [Member]

Collateralized Mortgage Backed Securities [Member]

Asset-backed Securities [Member]

Equity Securities [Member]

Equity Method and Other Investments [Member]

Buy euro Sell US dollar [Member]

Buy USD Sell Euro [Member]

Buy GBP Sell Euro [Member]

Buy USD Sell Japanese Yen [Member]

USD ($)

Equity Contract [Member]

Interest Rate Contract [Member]

Foreign Exchange Contract [Member]

USD ($)

Equity Contract [Member]

Interest Rate Contract [Member]

Foreign Exchange Contract [Member]

USD ($)

Equity Contract [Member]

Interest Rate Contract [Member]

Foreign Exchange Contract [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 2 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

Fair Value, Inputs, Level 1 [Member]

Estimate of Fair Value, Fair Value Disclosure [Member]

Carrying (Reported) Amount, Fair Value Disclosure [Member]

Available-for-Sale Securities, Amortized Cost [Member]

USD ($)

EUR (€)

USD ($)

EUR (€)

GBP (£)

USD ($)

JPY (¥)

Other Liabilities [Member]

Other Assets [Member]

Other Liabilities [Member]

Other Assets [Member]

Other Liabilities [Member]

Other Assets [Member]

Other Liabilities [Member]

Other Assets [Member]

Other Liabilities [Member]

Other Assets [Member]

Other Liabilities [Member]

Other Assets [Member]

Other Liabilities [Member]

USD ($)

Derivative Liability, Notional Amount

€ 520.70

$462.60

£ 180.7

$234.40

Derivative Asset, Notional Amount

716.8

337.6

216

24,350

Proceeds from Sale of Available-for-sale Securities

13,753.50

6,529.80

2,268.30

Cash and Cash Equivalents, Fair Value Disclosure

3,830.20

4,018.80

3,830.20

4,018.80

3,772.60

3,964.40

57.6

54.4

3,830.20

4,018.80

Long-term Debt

-5,212.90

-5,531.30

-5,212.90

-5,531.30

-5,490.90

-5,996.60

-5,490.90

-5,996.60

Derivative Assets, Current

20.1

6.7

20.1

6.7

20.1

6.7

Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets

90.00%

Maximum Remaining Maturity of Foreign Currency Derivatives

'30 days

Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate

65.00%

Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge

-308.2

51.5

259.6

Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments

308.2

-51.5

-259.6

Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net

8.8

Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion

Derivative Instruments, Gain (Loss) Recognized in Income, Net

15.4

-35.8

97.4

Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net

16.7

-149.6

35.6

Derivative Assets, Noncurrent

278.7

589.4

278.7

589.4

278.7

589.4

Derivative Liability, Noncurrent

-0.9

Derivative Liabilities, Current

-149.6

-7.1

-17.5

-149.6

-7.1

-17.5

-149.6

-7.1

-17.5

Available-for-sale Securities, Gross Unrealized Gains

375.6

140.5

Available-for-sale Securities, Gross Unrealized Losses

59.8

Available-for-sale Securities, Continuous Unrealized Gain Position, Fair Value

4,982.70

5,246

Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value

3,664.70

2,102

Other than Temporary Impairment Losses, Investments

11.3

22.6

31.1

Available-for-sale Securities, Gross Realized Gains

49.5

82.3

140

Available-for-sale Securities, Gross Realized Losses

15.4

10.9

9.9

Available-for-sale Securities, Current [Abstract]

Available-for-sale Securities, Debt Securities, Current

931.7

1,503.50

929.8

1,501.50

931.7

1,503.50

931.7

1,503.50

276.4

150.2

276.6

150.2

276.4

150.2

276.4

150.2

2.7

11.8

2.7

11.8

2.7

11.8

2.7

11.8

Available-for-sale Securities, Equity Securities

356.3

Available-for-sale Securities, Current, Total

1,567.10

1,665.50

1,284.10

1,663.50

Available-for-sale Securities, Noncurrent [Abstract]

Available-for-sale Securities, Debt Securities, Noncurrent

4,940.50

3,351.30

4,933.70

3,322.90

4,940.50

3,351.30

4,940.50

3,351.30

1,115.60

1,362.70

1,126.10

1,360.30

1,035.60

1,122.40

240.3

1,115.60

1,362.70

7.3

3.3

8.3

3.3

7.3

3.3

7.3

3.3

636

668.1

652.4

677.7

636

668.1

636

668.1

490

519

494.5

523.5

490

519

490

519

Available-for-sale Securities, Equity Securities, Noncurrent

81.2

175.8

22.8

81.2

175.8

81.2

175.8

354.3

233.7

354.3

233.7

Available-for-sale Securities, Noncurrent, Total

7,624.90

6,313.90

7,592.10

6,204.40

Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value

1,210.80

Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value

5,977.40

Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value

471.3

Available-for-sale Securities, Debt Maturities, after Ten Years, Fair Value

740.7

Available-for-sale Securities, Debt Securities

8,400.20

Derivative, Notional Amount

500

Maximum Length of Time Hedged in Interest Rate Cash Flow Hedge

'30 years

Short-term borrowings and current maturies of long-term debt

$1,012.60

$11.90

$1,000

Goodwill_and_Other_Intangibles2

Goodwill and Other Intangibles (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Finite-Lived Intangible Assets, Gross	$5,300.90	$5,237.40	'
Impairment of Intangible Assets, Finite-lived	0	0	0
Goodwill, Impairment Loss	0	0	0
Goodwill	1,516.80	1,501.30	'
Indefinite-Lived Intangible Assets (Excluding Goodwill)	'	65	'
Indefinite-Lived Intangible Assets, Gross	1,550.40	1,566.30	'
Finite-Lived Intangible Assets, Accumulated Amortization	2,520.20	2,051	'
Finite-Lived Intangible Assets, Net	2,780.70	3,186.40	'
Finite-Lived Intangible Assets, Weighted-Average Useful Life	'8 years	'	'
Finite-Lived Intangible Assets, Amortization Expense	555	563	469
Future Amortization Expense, Year One	530	'	'
Future Amortization Expense, Year Two	490	'	'
Future Amortization Expense, Year Three	380	'	'
Future Amortization Expense, Year Four	200	'	'
Future Amortization Expense, Year Five	180	'	'
Impairment charges, indefinite lived intangibles	0	205	151.5
In-process Research and Development [Member]	'	'	'
Indefinite-Lived Intangible Assets (Excluding Goodwill)	33.6	'	'
Human Pharmaceutical Products [Member]	'	'	'
Goodwill	1,354.70	1,364.20	'
Animal Health Products [Member]	'	'	'
Goodwill	162.1	137.1	'
Developed Technology Rights [Member]	'	'	'
Finite-Lived Intangible Assets, Gross	5,136.10	5,107.90	'
Finite-Lived Intangible Assets, Accumulated Amortization	2,447.20	1,987	'
Finite-Lived Intangible Assets, Net	2,688.90	3,120.90	'
Other Intangible Assets [Member]	'	'	'
Finite-Lived Intangible Assets, Gross	164.8	129.5	'
Finite-Lived Intangible Assets, Accumulated Amortization	73	64	'
Finite-Lived Intangible Assets, Net	$91.80	$65.50	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property and Equipment [Abstract]	'	'	'
Depreciation	$774.80	$754	$732.40
Land	198.7	201.4	'
Buildings	6,489.90	6,373.80	'
Equipment	7,752.70	7,542.90	'
Construction in progress	1,205.40	799.9	'
Property and equipment, gross	15,646.70	14,918	'
Less accumulated depreciation	-7,671.20	-7,157.80	'
Property and equipment, net	7,975.50	7,760.20	'
Interest Costs, Capitalized During Period	24.1	21	25.7
Operating Leases, Rent Expense	$227.20	$262.20	$267.40

Borrowings_Details

Borrowings (Details) (USD $)	12 Months Ended
Borrowings (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	4.20%	'	'
Repayments of Long-term Debt	$10,500,000	$1,511,100,000	$61,700,000
Notes Payable	4,887,300,000	4,887,300,000	'
Other Notes Payable	27,100,000	37,400,000	'
Long-term Debt, Fair Value Adjustment	298,500,000	606,600,000	'
Long-term Debt, Total	5,212,900,000	5,531,300,000	'
Long-term Debt, Current Maturities	-1,012,600,000	-11,900,000	'
Long-term debt	4,200,300,000	5,519,400,000	'
Description of Derivative Activity Volume Percent	65.00%	'	'
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	1,010,000,000	'	'
Long-term Debt, Maturities, Repayments of Principal in Year Two	9,500,000	'	'
Long-term Debt, Maturities, Repayments of Principal in Year Three	205,600,000	'	'
Long-term Debt, Maturities, Repayments of Principal in Year Four	1,000,000,000	'	'
Long-term Debt, Maturities, Repayments of Principal in Year Five	200,300,000	'	'
Line of Credit Facility, Remaining Borrowing Capacity	1,360,000,000	'	'
Line of Credit Facility, Collateral, Amount	1,200,000,000	'	'
Line of Credit Facility, Amount Outstanding	0	'	'
Interest Paid, Net	$139,700,000	$171,900,000	$167,400,000
Debt Instrument, Interest Rate, Effective Percentage	3.10%	3.20%	'
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum	7.13%	'	'

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	$144.90	$141.50	$147.40	'
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	50.7	49.5	51.6	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	100,000,000	'	'	'
Performance Shares [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	18.9	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'12 months	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	700,000	1,600,000	3,900,000	'
Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued	600,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$50.19	$35.74	$31.90	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'2 years	'	'	'
Shareholder Value Awards [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	51.6	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'20 months	'	'	'
Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued	2,200,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$45.17	$30.35	$28.33	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	3.50%	4.50%	4.90%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	0.43%	0.36%	1.36%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.08%	0.10%	0.20%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	18.95%	22.40%	27.61%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	22.37%	25.64%	29.10%	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	6,636,000	7,539,000	7,036,000	6,381,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,795,000	2,439,000	2,561,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	-2,397,000	-973,000	-428,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	-301,000	-963,000	-1,478,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'3 years	'	'	'
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	58.4	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'21 months	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	800,000	300,000	200,000	'
Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued	800,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$54.10	$39.65	$35.80	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,100,000	1,400,000	1,500,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'3 years	'	'	'
Employee Stock Option [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'3 years	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	'10	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	16,140,000	27,232,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$66.66	$63.89	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	-208,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$54.27	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	-10,884,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price	$59.95	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	'0 years 8 months	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	0	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	16,140,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$66.66	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	'0 years 8 months	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$0	'	'	'

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2000

Dec. 31, 2013

Dec. 31, 2012

Oct. 31, 2013

Dec. 31, 2013

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Treasury Stock [Member]

2000 Share Repurchase Program [Member]

2012 Share Repurchase Program [Member]

2013 Share Repurchase Program [Member]

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest

$17,640,700,000

$14,773,900,000

$17,640,700,000

$14,773,900,000

Common stock shares in treasury, shares in thousands

833,000

2,850,000

833,000

2,850,000

Net income

727,500,000

1,203,100,000

1,206,200,000

1,548,000,000

827,200,000

1,326,600,000

923,600,000

1,011,100,000

4,684,800,000

4,088,600,000

4,347,700,000

4,684,800,000

4,088,600,000

4,347,700,000

Treasury Stock, Retired, Cost Method, Amount

100,000

-100,000

-1,677,800,000

-711,700,000

1,698,100,000

721,100,000

100,000

-419,200,000

-1,100,000,000

-400,000,000

-500,000,000

Stock Repurchased During Period, Shares

Stock Repurchase Program, Authorized Amount

3,000,000,000

1,500,000,000

5,000,000,000

Stock Repurchase Program, Remaining Authorized Repurchase Amount

4,500,000,000

Treasury Stock, Shares, Retired

-32,406,000

-14,912,000

-1,000

Preferred Stock, Shares Authorized

5,000,000

Preferred Stock, Shares Issued

Common Stock, Shares Held in Employee Trust, Shares

50,000,000

Employee benefit trust

3,013,200,000

Other comprehensive income (loss)

1,794,400,000

61,500,000

-1,188,500,000

Allocated Share-based Compensation Expense

$144,900,000

$141,500,000

$147,400,000

Issued shares, shares in thousands

1,117,628,000

1,146,493,000

1,117,628,000

1,146,493,000

Earnings_Loss_Per_Share_Detail

Earnings (Loss) Per Share (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net income	$727.50	$1,203.10	$1,206.20	$1,548	$827.20	$1,326.60	$923.60	$1,011.10	$4,684.80	$4,088.60	$4,347.70
Weighted Average Number of Shares Outstanding, Basic	'	'	'	'	'	'	'	'	1,080,874	1,113,178	1,113,923
Earnings per share - basic	$0.68	$1.11	$1.12	$1.42	$0.75	$1.18	$0.83	$0.91	$4.33	$3.67	$3.90
Weighted Average Number of Shares Outstanding, Diluted	'	'	'	'	'	'	'	'	1,084,766	1,117,294	1,113,967
Earnings per share - diluted	$0.67	$1.11	$1.11	$1.42	$0.74	$1.18	$0.83	$0.91	$4.32	$3.66	$3.90

Income_Taxes_Composition_and_D

Income Taxes (Composition and Deferreds) (Details) (USD $)	12 Months Ended
Income Taxes (Composition and Deferreds) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Unremitted Earnings of Foreign Subsidiaries	$23,740,000,000	'	'
Current Federal Tax Expense (Benefit)	259,100,000	596,800,000	671,400,000
Current Foreign Tax Expense (Benefit)	553,200,000	540,600,000	759,500,000
Current State and Local Tax Expense (Benefit)	126,300,000	56,200,000	-22,900,000
Current Income Tax Expense (Benefit), Total	938,600,000	1,193,600,000	1,408,000,000
Deferred Federal Income Tax Expense (Benefit)	297,000,000	87,000,000	-398,500,000
Deferred Foreign Income Tax Expense (Benefit)	-28,200,000	29,900,000	-34,700,000
Deferred State and Local Income Tax Expense (Benefit)	-2,900,000	9,100,000	27,000,000
Deferred Income Tax Expense (Benefit), Total	265,900,000	126,000,000	-406,200,000
Income taxes	1,204,500,000	1,319,600,000	1,001,800,000
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits	639,800,000	1,081,800,000	'
Tax Credit Carryforward, Deferred Tax Asset	494,600,000	703,200,000	'
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves	313,700,000	153,800,000	'
Deferred Tax Assets, Operating Loss Carryforwards	311,700,000	370,100,000	'
Deferred Tax Assets, Goodwill and Intangible Assets	418,800,000	366,800,000	'
Deferred Tax Assets, Inventory	104,500,000	159,600,000	'
Deferred Tax Assets, Deferred Income	76,500,000	278,600,000	'
Deferred Tax Asset, Fair Value Adjustments	110,000,000	232,800,000	'
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies	106,000,000	113,200,000	'
Deferred Tax Assets, Other	518,500,000	361,500,000	'
Deferred Tax Assets, Gross, Total	3,094,100,000	3,821,400,000	'
Deferred Tax Assets, Valuation Allowance	-647,100,000	-675,800,000	'
Deferred Tax Assets, Net, Total	2,447,000,000	3,145,600,000	'
Deferred Tax Liabilities, Undistributed Foreign Earnings	-898,300,000	-920,400,000	'
Deferred Tax Liabilities, Goodwill and Intangible Assets	-598,900,000	-708,800,000	'
Deferred Tax Liabilities, Prepaid Expenses	-446,200,000	0	'
Deferred Tax Liabilities, Deferred Expense, Capitalized Inventory Costs	-685,600,000	-573,400,000	'
Deferred Tax Liabilities, Property, Plant and Equipment	-379,100,000	-407,100,000	'
Deferred Tax Liabilities, Derivatives	109,600,000	257,000,000	'
Deferred Tax Liabilities, Total	3,117,700,000	2,866,700,000	'
Deferred Tax Assets (Liabilities), Net, Total	-670,700,000	278,900,000	'
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	81,000,000	'	'
Deferred Tax Assets, Tax Credit Carryforwards, Other	9,800,000	'	'
Carryforward [Member]	'	'	'
Operating Loss Carryforwards	662,500,000	'	'
Tax Credit Carryforward, Amount	494,600,000	'	'
Carryback [Member]	'	'	'
Tax Credit Carryforward, Amount	2,900,000	'	'
Expiration 5 years [Member]	'	'	'
Operating Loss Carryforwards	262,800,000	'	'
Expiration 5-20 years [Member]	'	'	'
Operating Loss Carryforwards	356,800,000	'	'
Expiration 5-20 years, Minimum [Member]	'	'	'
Operating Loss Carryforwards, Expiration Dates	31-Dec-18	'	'
Expiration 5-20 years, Maximum [Member]	'	'	'
Operating Loss Carryforwards, Expiration Dates	31-Dec-33	'	'
Expiration 10-20 years [Member]	'	'	'
Tax Credit Carryforward, Amount	183,800,000	'	'
Expiration 10-20 years, Minimum [Member]	'	'	'
Other Tax Carryforward, Expiration Dates	31-Dec-23	'	'
Expiration 10-20 years, Maximum [Member]	'	'	'
Other Tax Carryforward, Expiration Dates	31-Dec-33	'	'
No Expiration [Member]	'	'	'
Operating Loss Carryforwards	42,900,000	'	'
Tax Credit Carryforward, Amount	4,900,000	'	'
Internal Revenue Service (IRS) [Member] \| Designated Unusable [Member]	'	'	'
Tax Credit Carryforward, Amount	80,300,000	'	'
State and Local Jurisdiction [Member] \| Designated Unusable [Member]	'	'	'
Tax Credit Carryforward, Amount	117,400,000	'	'
Foreign Tax Authority [Member] \| Designated Unusable [Member]	'	'	'
Tax Credit Carryforward, Amount	$105,300,000	'	'

Income_Taxes_Income_Tax_Expens

Income Taxes (Income Tax Expense and Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Domestic Contribution to Income before Income Taxes	61.00%	54.00%	24.00%
Income Taxes Paid	$1,260	$992	$942.80
Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate	2,061.30	1,892.90	1,872.30
Income Tax Reconciliation, Deductions, Extraterritorial Income Exclusion	-778.3	-593.8	-796.7
Income Tax Reconciliation, Tax Credits	-175.6	-11.2	-80.8
Income Tax Reconciliation, Tax Settlements, Domestic	-7.9	0	-85.3
Income Tax Reconciliation, Other Adjustments	105	31.7	92.3
Income taxes	1,204.50	1,319.60	1,001.80
Unrecognized Tax Benefits, Beginning Balance	1,534.30	1,369.30	1,714.30
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions	142.5	144.8	89.4
Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions	251.5	70.1	390
Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions	-358.2	-38.5	-492.3
Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations	-24.9	-4.6	-2.6
Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities	-404.9	-9.2	-326.3
Unrecognized Tax Benefits, Increases Resulting from Foreign Currency Translation	-3.9	2.4	-3.2
Unrecognized Tax Benefits, Ending Balance	1,136.40	1,534.30	1,369.30
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	523.3	928.1	'
Tax Adjustments, Settlements, and Unusual Provisions	'	'	85.3
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	135	'	300
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	-10.9	-42.3	-47.3
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	$161.50	$187.50	'

Retirement_Benefits_Schedule_o

Retirement Benefits (Schedule of Benefit Obligations and Plan Assets) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Benefit Obligation, Beginning Balance	$10,423.80	$9,191.20	'
Defined Benefit Plan, Service Cost	287.1	253.1	236.3
Defined Benefit Plan, Interest Cost	437.2	455.1	447.9
Defined Benefit Plan, Actuarial Net (Gains) Losses	-792.2	834	'
Defined Benefit Plan, Benefits Paid	-402.3	-404.2	'
Defined Benefit Plan, Plan Amendments	-0.1	-0.6	'
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Benefit Obligation	22.9	95.2	'
Defined Benefit Plan, Benefit Obligation, Ending Balance	9,976.40	10,423.80	9,191.20
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	8,286.60	7,186.30	'
Defined Benefit Plan, Actual Return on Plan Assets	1,144.60	922.7	'
Defined Benefit Plan, Contributions by Employer	428.9	469.7	'
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	23.9	112.1	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	9,481.70	8,286.60	7,186.30
Defined Benefit Plan, Funded Status of Plan	-494.7	-2,137.20	'
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), before Tax	3,546.30	5,187.50	'
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax	50.7	54.9	'
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total	3,102.30	3,105.20	'
Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Benefit Obligation, Beginning Balance	2,337.70	2,308.60	'
Defined Benefit Plan, Service Cost	49.9	63.3	72.4
Defined Benefit Plan, Interest Cost	98.1	114.9	118
Defined Benefit Plan, Actuarial Net (Gains) Losses	-642.5	-57	'
Defined Benefit Plan, Benefits Paid	-79.6	-67.2	'
Defined Benefit Plan, Plan Amendments	-4.1	-28.4	'
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Benefit Obligation	-2.3	3.5	'
Defined Benefit Plan, Benefit Obligation, Ending Balance	1,757.20	2,337.70	2,308.60
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,518	1,339	'
Defined Benefit Plan, Actual Return on Plan Assets	365.7	183.4	'
Defined Benefit Plan, Contributions by Employer	75.5	62.8	'
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	0	0	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,879.60	1,518	1,339
Defined Benefit Plan, Funded Status of Plan	122.4	-819.7	'
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), before Tax	178.1	1,156.70	'
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax	-171.5	-203.4	'
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total	129	133.6	'
Fair Value, Inputs, Level 2 [Member] \| Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	4,860.10	4,363.10	'
Fair Value, Inputs, Level 2 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,533.90	1,229.90	'
Fair Value, Inputs, Level 3 [Member] \| Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	2,603.20	2,274.90	2,256.60
Fair Value, Inputs, Level 3 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	211.1	182.2	185.2
Fair Value, Inputs, Level 1 [Member] \| Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	2,018.40	1,648.60	'
Fair Value, Inputs, Level 1 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	134.6	105.9	'
Equity Securities [Member] \| Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	400.3	457.7	'
Equity Securities [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	39.4	45.4	'
Equity Securities [Member] \| Fair Value, Inputs, Level 2 [Member] \| Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	211.1	149.8	'
Equity Securities [Member] \| Fair Value, Inputs, Level 2 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	21.1	15	'
Equity Securities [Member] \| Fair Value, Inputs, Level 1 [Member] \| Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	189.2	307.9	'
Equity Securities [Member] \| Fair Value, Inputs, Level 1 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	18.3	30.4	'
Equity Securities - International [Member] \| Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	2,483.80	1,905.30	'
Equity Securities - International [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	167.2	127.7	'
Equity Securities - International [Member] \| Fair Value, Inputs, Level 2 [Member] \| Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,438	1,232	'
Equity Securities - International [Member] \| Fair Value, Inputs, Level 2 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	105.6	93.8	'
Equity Securities - International [Member] \| Fair Value, Inputs, Level 1 [Member] \| Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,045.80	673.3	'
Equity Securities - International [Member] \| Fair Value, Inputs, Level 1 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	61.6	33.9	'
Fixed Income Funds Developed Markets [Member] \| Fair Value, Inputs, Level 2 [Member] \| Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	'	915.3	'
Fixed Income Funds Developed Markets [Member] \| Fair Value, Inputs, Level 3 [Member] \| Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	'	3.7	'
Fixed Income Funds Developed Markets [Member] \| Fair Value, Inputs, Level 1 [Member] \| Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	'	$156.40	'

Retirement_Benefits_Schedule_o1

Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent	$1,549.40	$3,012.40
Pension Plans, Defined Benefit [Member]	'	'
Defined Benefit Plan, Amortization of Net Gains (Losses)	-277.2	'
Defined Benefit Plan, Current Assets	881.2	125.5
Pension and Other Postretirement Defined Benefit Plans, Current Liabilities	-62.8	-61.2
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent	1,313.10	2,201.60
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax	3,597	5,242.50
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total	3,102.30	3,105.20
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	-414.7	'
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax	-3.7	'
Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'
Defined Benefit Plan, Amortization of Net Gains (Losses)	-20	'
Defined Benefit Plan, Current Assets	366.4	0
Pension and Other Postretirement Defined Benefit Plans, Current Liabilities	-7.7	-8.9
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent	236.3	810.8
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax	6.6	953.3
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total	129	133.6
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	-100.5	'
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax	$35.60	'

Retirement_Benefits_Schedule_o2

Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Defined Benefit Plan, Health Care Cost Trend Rate Assumed for Next Fiscal Year	6.60%	'	'
Defined Benefit Plan, Direction and Pattern for Assumed Health Care Cost Trend Rate	0.30%	'	'
Defined Benefit Plan, Ultimate Health Care Cost Trend Rate	5.00%	'	'
Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	4.90%	4.30%	5.00%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	4.30%	5.00%	5.60%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	3.40%	3.40%	3.70%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase	3.40%	3.70%	3.70%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets	8.40%	8.40%	8.50%
Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	5.00%	4.30%	5.10%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	4.30%	5.10%	5.80%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets	8.80%	8.80%	8.80%

Retirement_Benefits_Schedule_o3

Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Defined Benefit Plan, Accumulated Benefit Obligation	$9,130,000,000	$9,460,000,000	'
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Accumulated Benefit Obligation	1,384,600,000	8,021,000,000	'
Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Benefit Obligation	1,773,600,000	9,151,200,000	'
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets	395,400,000	6,888,600,000	'
Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets	181,800,000	6,580,600,000	'
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	-31,900,000	'	'
Defined Benefit Plan, Effect of One Percentage Point Increase on Accumulated Postretirement Benefit Obligation	169,700,000	'	'
Defined Benefit Plan, Effect of One Percentage Point Increase on Service and Interest Cost Components	9,400,000	'	'
Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation	149,100,000	'	'
Defined Benefit Plan, Effect of One Percentage Point Decrease on Service and Interest Cost Components	7,600,000	'	'
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax	-515,200,000	'	'
Defined benefit pension and retiree health benefit plans	-2,592,200,000	128,600,000	1,240,200,000
Defined Contribution Plan, Cost Recognized	147,700,000	136,300,000	124,800,000
Pension Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year One	-430,900,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	-440,100,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	-453,000,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	-469,000,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	-486,000,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	-2,726,000,000	'	'
Defined Benefit Plan, Service Cost	287,100,000	253,100,000	236,300,000
Defined Benefit Plan, Interest Cost	437,200,000	455,100,000	447,900,000
Defined Benefit Plan, Expected Return on Plan Assets	-701,900,000	-684,800,000	-685,900,000
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	3,700,000	4,200,000	8,600,000
Defined Benefit Plan, Amortization of Gains (Losses)	414,700,000	285,700,000	200,400,000
Defined Benefit Plan, Amortization of Net Gains (Losses)	277,200,000	'	'
Defined Benefit Plan, Future Amortization of Prior Service Cost (Credit)	3,600,000	'	'
Defined Benefit Plan, Net Periodic Benefit Cost, Total	440,800,000	313,300,000	207,300,000
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax	-1,234,700,000	'	'
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During Period, before Tax	100,000	'	'
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax	-3,700,000	'	'
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	-414,700,000	'	'
Defined Benefit Plan, Amount to be Amortized from Accumulated Other Comprehensive Income (Loss) Next Fiscal Year	280,800,000	'	'
Foreign currency translation gains (losses)	-7,700,000	'	'
Defined benefit pension and retiree health benefit plans	1,645,500,000	'	'
Other Postretirement Benefit Plans, Defined Benefit [Member]	'	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year One	-87,200,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	-90,400,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	-94,100,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	-97,400,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	-101,200,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	-551,800,000	'	'
Defined Benefit Plan, Service Cost	49,900,000	63,300,000	72,400,000
Defined Benefit Plan, Interest Cost	98,100,000	114,900,000	118,000,000
Defined Benefit Plan, Expected Return on Plan Assets	-130,700,000	-127,200,000	-129,400,000
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	-35,600,000	-39,800,000	-42,900,000
Defined Benefit Plan, Amortization of Gains (Losses)	100,500,000	98,400,000	88,700,000
Defined Benefit Plan, Amortization of Net Gains (Losses)	20,000,000	'	'
Defined Benefit Plan, Future Amortization of Prior Service Cost (Credit)	-31,200,000	'	'
Defined Benefit Plan, Net Periodic Benefit Cost, Total	82,200,000	109,600,000	106,800,000
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax	-877,600,000	'	'
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During Period, before Tax	4,100,000	'	'
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax	35,600,000	'	'
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	-100,500,000	'	'
Defined Benefit Plan, Amount to be Amortized from Accumulated Other Comprehensive Income (Loss) Next Fiscal Year	-11,200,000	'	'
Foreign currency translation gains (losses)	100,000	'	'
Defined benefit pension and retiree health benefit plans	946,700,000	'	'
Other Postretirement Benefit Plans, Defined Benefit, Gross [Member]	'	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year One	-94,000,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	-98,000,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	-102,300,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	-106,400,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	-111,000,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	-612,300,000	'	'
Other Postretirement Benefit Plans, Defined Benefit Plans, Medicare Rebates [Member]	'	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year One	-6,800,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	-7,600,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	-8,200,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	-9,000,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	-9,800,000	'	'
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	($60,500,000)	'	'

Retirement_Benefits_Fair_Value

Retirement Benefits (Fair Value Disclosures) (Details) (USD $)

12 Months Ended

In Millions, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Fixed Income Funds [Member]

Equity Funds [Member]

Equity Securities [Member]

Equity Securities - International [Member]

Fixed Income Funds, Emerging Markets [Member]

Hedge Funds [Member]

Real Estate [Member]

Other Assets [Member]

Other Contract [Member]

Other Plan Assets [Member]

Fair Value, Inputs, Level 1 [Member]

Fair Value, Inputs, Level 2 [Member]

Fair Value, Inputs, Level 3 [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Fixed Income Funds [Member]

Fixed Income Funds Developed Markets [Member]

Equity Funds [Member]

Equity Securities [Member]

Equity Securities - International [Member]

Real Estate [Member]

Other Assets [Member]

Other Plan Assets [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Fixed Income Funds [Member]

Fixed Income Funds Developed Markets [Member]

Equity Funds [Member]

Equity Securities [Member]

Equity Securities - International [Member]

Fixed Income Funds, Emerging Markets [Member]

Hedge Funds [Member]

Real Estate [Member]

Other Assets [Member]

Other Contract [Member]

Other Plan Assets [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Fixed Income Funds [Member]

Fixed Income Funds Developed Markets [Member]

Equity Funds [Member]

Hedge Funds [Member]

Real Estate [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Other Postretirement Benefit Plans, Defined Benefit [Member]

Pension Plans, Defined Benefit [Member]

Defined Benefit Plan, Percentage of Global Investments in Plan Assets

80.00%

Defined Benefit Plan, Target Allocation Percentage of Assets

20.00%

80.00%

Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance

$1,879.60

$1,518

$1,339

$9,481.70

$8,286.60

$7,186.30

$54.70

$59.40

$1,036.10

$1,075.40

$88.90

$81.90

$1,069.90

$991.20

$39.40

$45.40

$400.30

$457.70

$167.20

$127.70

$2,483.80

$1,905.30

$38.20

$40.30

$382.60

$402.30

$266.40

$234

$2,902.30

$2,555.50

$36.70

$35.40

$521.40

$504.30

$51.30

$685.30

$1,136.80

$869.10

$24.80

$394.90

$134.60

$105.90

$2,018.40

$1,648.60

$170.20

$156.40

$17.40

$18.30

$30.40

$189.20

$307.90

$61.60

$33.90

$1,045.80

$673.30

$36.70

$35.40

$368

$353.50

$18

$245.20

$6.20

$140.10

$1,533.90

$1,229.90

$4,860.10

$4,363.10

$53.10

$59

$850

$915.30

$76.40

$63.30

$21.10

$15

$211.10

$149.80

$105.60

$93.80

$1,438

$1,232

$38.20

$40.30

$382.60

$402.30

$145.80

$134.10

$1,461.90

$1,337.40

$8.20

$33.30

$440.10

$1,136.80

$869.10

$18.60

$254.80

$211.10

$182.20

$2,603.20

$2,274.90

$1.60

$0.40

$15.90

$3.70

$88.90

$81.90

$993.50

$910.50

$120.60

$99.90

$1,440.40

$1,218.10

$153.40

$142.60

Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance

1,879.60

1,518

1,339

9,481.70

8,286.60

7,186.30

54.7

59.4

1,036.10

1,075.40

88.9

81.9

1,069.90

991.2

39.4

45.4

400.3

457.7

167.2

127.7

2,483.80

1,905.30

38.2

40.3

382.6

402.3

266.4

234

2,902.30

2,555.50

36.7

35.4

521.4

504.3

51.3

685.3

1,136.80

869.1

24.8

394.9

134.6

105.9

2,018.40

1,648.60

170.2

156.4

17.4

18.3

30.4

189.2

307.9

61.6

33.9

1,045.80

673.3

36.7

35.4

368

353.5

245.2

6.2

140.1

1,533.90

1,229.90

4,860.10

4,363.10

53.1

850

915.3

76.4

63.3

21.1

211.1

149.8

105.6

93.8

1,438

1,232

38.2

40.3

382.6

402.3

145.8

134.1

1,461.90

1,337.40

8.2

33.3

440.1

1,136.80

869.1

18.6

254.8

182.2

185.2

2,274.90

2,256.60

0.4

3.7

81.9

79.9

910.5

870.2

99.9

105.3

1,218.10

1,248.40

142.6

138

Defined Benefit Plan, Actual Return on Plan Assets Still Held

23.9

-0.9

284.6

-0.3

-3

0.3

13.9

155.7

10.1

10.3

-0.9

123.4

18.3

8.5

3.3

Defined Benefit Plan, Actual Return on Plan Assets Sold During Period

-0.2

Defined Benefit Plan, Purchases, Sales, and Settlements

3.9

32.2

0.4

3.7

-6.9

-72.7

10.4

98.9

2.3

Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets

-2.2

-14.6

0.3

2.3

30.2

-4.5

-48.4

1.3

Defined Benefit Plan, Transfers Between Measurement Levels

$1.10

$0.10

$11.50

$1.10

$0.10

$11.50

$1.10

Contingencies_Details

Contingencies (Details)	12 Months Ended
Contingencies (Details)	Dec. 31, 2013	Dec. 31, 2012
Byetta [Member] \| Product Liability Litigation [Member]	'	'
Loss Contingency, Number of Lawsuits	275	'
Loss Contingency, Number of Plaintiffs	700	'
Prozac [Member] \| Product Liability Litigation [Member]	'	'
Loss Contingency, Number of Claimants	370	'
Loss Contingency, Number of Lawsuits	10	'
Product Liability Litigation [Member] \| Byetta [Member]	'	'
Loss Contingency, Number of Claimants	460	'
Damages from Product, Cancer [Member] \| Byetta [Member] \| Product Liability Litigation [Member]	'	'
Loss Contingency, Number of Lawsuits	190	'
Loss Contingency, Number of Plaintiffs	'	265
Brazil [Member] \| Employee Litigation [Member]	'	'
Loss Contingency, Number of Lawsuits	30	'
California [Member] \| Product Liability Litigation [Member] \| Byetta [Member]	'	'
Loss Contingency, Number of Lawsuits	95	'
Loss Contingency, Number of Plaintiffs	510	'

Other_Comprehensive_Income_Los2

Other Comprehensive Income (Loss) (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	($31.90)	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	-2,002.70	-3,797.10	'	'
Other comprehensive income (loss)	1,794.40	61.5	-1,188.50	'
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, Tax	886.1	34.4	-383.8	'
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax	71.6	30.8	-64.4	'
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax	515.2	'	'	'
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Gain (Loss), before Tax	483.3	'	'	'
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net (Gain) Loss, Tax	-164.3	'	'	'
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net (Gain) Loss, Net of Tax	319	'	'	'
Other Comprehensive Income, Other, Net of Tax	-0.3	'	'	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	318.7	'	'	'
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax	-43.2	'	'	'
Accumulated Other Comprehensive Income (Loss) [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	-2,002.70	-3,797.10	-3,858.60	-2,670.10
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	-1,475.70	'	'	'
Other comprehensive income (loss)	1,794.40	61.5	-1,188.50	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	318.7	'	'	'
Accumulated Translation Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	463	426.8	265.9	510.7
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	-36.2	'	'	'
Other comprehensive income (loss)	36.2	160.9	-244.8	'
Accumulated Net Unrealized Investment Gain (Loss) [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	205.2	72.5	14.8	128.9
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	-138.9	'	'	'
Other comprehensive income (loss)	132.7	57.7	-114.1	'
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax	'	104.1	59.4	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	-6.2	'	'	'
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	'	-46.4	-54.7	'
Accumulated Defined Benefit Plans Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	-2,489.10	-4,195.20	-4,032.20	-3,175.80
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	-1,387.10	'	'	'
Other comprehensive income (loss)	1,706.10	-163	-856.4	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	319	'	'	'
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss), Net of Tax	-181.8	-101.2	-107.1	-133.9
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	86.5	'	'	'
Other comprehensive income (loss)	-80.6	5.9	26.8	'
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	'	0	32.6	'
Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax	'	5.9	5.8	'
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	$5.90	'	'	'

Other_Net_Expense_Income_Detai

Other - Net, Expense (Income) (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Other Revenue, Net	'	'	'	'	'	'	'	'	$707.50	$633	$681.70
Income related to termination of the exenatide collaboration with Amylin	'	'	'	'	'	'	'	'	-495.4	-787.8	0
Interest Expense	'	'	'	'	'	'	'	'	160.1	177.8	186
Investment Income, Interest	'	'	'	'	'	'	'	'	-119.7	-105	-79.9
Other (income)expense	'	'	'	'	'	'	'	'	-63.9	41	72.9
Nonoperating Income (Expense), Total	-9.1	31.3	-11.9	-529.2	52	-788.5	16.5	46	-518.9	-674	179
Exenatide [Member]	'	'	'	'	'	'	'	'	'	'	'
Other Revenue, Net	'	'	'	'	'	'	'	'	0	70.1	243.1
Other (income)expense	'	'	'	'	'	'	'	'	($495.40)	'	'

Segment_Information_Segment_In1

Segment Information Segment Information (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Depreciation and amortization	'	'	'	'	'	'	'	'	$1,445.60	$1,462.20	$1,373.60
Revenue	5,808.80	5,772.60	5,929.70	5,602	5,957.30	5,443.30	5,600.70	5,602	23,113.10	22,603.40	24,286.50
Long-Lived Assets	8,741.30	'	'	'	8,990.50	'	'	'	8,741.30	8,990.50	9,372.40
Asset impairment, restructuring, and other special charges	-35.4	0	-63.5	-21.7	-204	-53.3	0	-23.8	-120.6	-281.1	-401.4
Income before income taxes	909.9	1,513.40	1,514.90	1,951.10	1,012.40	1,874.70	1,185.70	1,335.30	5,889.30	5,408.20	5,349.50
Acquired in-process research and development	-57.1	0	0	0	'	'	'	'	-57.1	0	-388
Gain (Loss) on Contract Termination	'	'	'	'	'	'	'	'	495.4	787.8	0
Accounts Receivable, Minimum [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Concentration Risk, Percentage	'	'	'	'	'	'	'	'	9.00%	9.00%	9.00%
Accounts Receivable, Maximum [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Concentration Risk, Percentage	'	'	'	'	'	'	'	'	18.00%	18.00%	18.00%
Customer Concentration Risk, Minimum [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Concentration Risk, Percentage	'	'	'	'	'	'	'	'	10.00%	10.00%	10.00%
Customer Concentration Risk, Maximum [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Concentration Risk, Percentage	'	'	'	'	'	'	'	'	19.00%	19.00%	19.00%
United States [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	12,889.70	12,313.10	12,977.20
Long-Lived Assets	4,649.60	'	'	'	5,064.70	'	'	'	4,649.60	5,064.70	5,485.30
Europe [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	4,338.40	4,259.70	5,290.90
Long-Lived Assets	2,469.70	'	'	'	2,281.10	'	'	'	2,469.70	2,281.10	2,220.20
Japan [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	2,063.80	2,246.20	2,104.10
Long-Lived Assets	81.1	'	'	'	101.5	'	'	'	81.1	101.5	102.9
Other Foreign Countries [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	3,821.20	3,784.40	3,914.30
Long-Lived Assets	1,540.90	'	'	'	1,543.20	'	'	'	1,540.90	1,543.20	1,564
Total segment [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Income before income taxes	'	'	'	'	'	'	'	'	5,571.60	4,901.50	6,138.90
Endocrinology [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	7,304.40	6,810.90	6,806.70
Neuroscience [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	7,216.20	7,575.10	9,723.80
Oncology [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	3,268.50	3,281.60	3,322.20
Cardiovascular [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	2,923.20	2,632.50	2,486.40
Other Pharmaceuticals [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	249.3	266.8	268.8
Pharmaceutical Products Total [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	20,961.60	20,566.90	22,607.90
Income before income taxes	'	'	'	'	'	'	'	'	5,015	4,393.40	5,837.90
Animal Health Products [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	2,151.50	2,036.50	1,678.60
Income before income taxes	'	'	'	'	'	'	'	'	556.6	508.1	301
Human Pharmaceutical Products [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Depreciation and amortization	'	'	'	'	'	'	'	'	1,350	1,370	1,300
Amylin [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Gain (Loss) on Contract Termination	'	'	'	'	'	'	'	'	495.4	787.8	0
Animal Health Products [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Depreciation and amortization	'	'	'	'	'	'	'	'	99.4	91.1	78.1
Cymbalta [Member] \| United States [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenue	'	'	'	'	'	'	'	'	$3,960	'	'

Selected_Quarterly_Data_Detail

Selected Quarterly Data (Details) (USD $)	3 Months Ended								12 Months Ended
In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenue	$5,808.80	$5,772.60	$5,929.70	$5,602	$5,957.30	$5,443.30	$5,600.70	$5,602	$23,113.10	$22,603.40	$24,286.50
Cost of sales	1,386.50	1,198.10	1,165.20	1,158.30	1,248.30	1,203.60	1,146.70	1,197.90	4,908.10	4,796.50	5,067.90
Operating Expenses	3,429	3,029.80	3,198	3,000.10	3,440.60	3,100.20	3,251.80	2,999	'	'	'
Acquired in-process research and development	57.1	0	0	0	'	'	'	'	57.1	0	388
Asset impairment, restructuring, and other special charges	35.4	0	63.5	21.7	204	53.3	0	23.8	120.6	281.1	401.4
Other-net, (income) expense	-9.1	31.3	-11.9	-529.2	52	-788.5	16.5	46	-518.9	-674	179
Income before income taxes	909.9	1,513.40	1,514.90	1,951.10	1,012.40	1,874.70	1,185.70	1,335.30	5,889.30	5,408.20	5,349.50
Net income	$727.50	$1,203.10	$1,206.20	$1,548	$827.20	$1,326.60	$923.60	$1,011.10	$4,684.80	$4,088.60	$4,347.70
Earnings per share - basic	$0.68	$1.11	$1.12	$1.42	$0.75	$1.18	$0.83	$0.91	$4.33	$3.67	$3.90
Earnings per share - diluted	$0.67	$1.11	$1.11	$1.42	$0.74	$1.18	$0.83	$0.91	$4.32	$3.66	$3.90
Common Stock, Dividends, Per Share, Cash Paid	$0.49	$0.49	$0.49	$0.49	$0.49	$0.49	$0.49	$0.49	'	'	'
High [Member]	'	'	'	'	'	'	'	'	'	'	'
Share Price	$51.34	$54.96	$58.33	$56.79	$53.81	$47.64	$42.91	$41.80	$51.34	$53.81	'
Low [Member]	'	'	'	'	'	'	'	'	'	'	'
Share Price	$47.65	$49.92	$49.06	$49.51	$45.91	$41.98	$39.18	$38.49	$47.65	$45.91	'